<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">mbx44FBJDxLTrYqcSCDkrxq</article-id>
      <article-id pub-id-type="other">00014</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001300014</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500314</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000098</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Associa&#231;&#227;o de betabloqueadores e treinamento f&#237;sico na insufici&#234;ncia card&#237;aca de camundongos</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Vanzelli</surname>
            <given-names>Andr&#233;a Somolanji</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Medeiros</surname>
            <given-names>Alessandra</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sirvente</surname>
            <given-names>Raquel de Assis</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salemi</surname>
            <given-names>Vera Maria Cury</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mady</surname>
            <given-names>Charles</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brum</surname>
            <given-names>Patricia Chakur</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Escola de Educa&#231;&#227;o F&#237;sica </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff03">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal de S&#227;o Paulo</institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>09</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>3</issue>
      <fpage>373</fpage>
      <lpage>380</lpage>
      <history>
        <date date-type="rev-recd">
          <day>11</day>
          <month>02</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>29</day>
          <month>09</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>03</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O tratamento da insufici&#234;ncia card&#237;aca (IC) conta atualmente com diversos tipos de interven&#231;&#245;es. Dentre elas, destacam-se a terapia com betabloqueadores (BB) e o treinamento f&#237;sico (TF). Contudo, os efeitos da associa&#231;&#227;o dessas terapias s&#227;o pouco estudados. OBJETIVO: Verificar os efeitos do tratamento com BB, metoprolol (M) e carvedilol (C) associados ao TF na IC em camundongos. M&#201;TODOS: Utilizamos modelo gen&#233;tico de IC induzida em camundongos por hiperatividade simp&#225;tica. Inicialmente, dividimos os animais com IC em: sedent&#225;rios (S); treinados (T); tratados com M (138 mg/kg) (M) ou C (65 mg/kg) (C). Na segunda parte, dividimos os grupos em S; treinado e tratado com M (MT) e treinado e tratado com C (CT). O TF consistiu em treinamento aer&#243;bico em esteira por 8 semanas. A toler&#226;ncia ao esfor&#231;o foi avaliada por teste progressivo m&#225;ximo e a fra&#231;&#227;o de encurtamento foi avaliada (FE) por ecocardiografia. O di&#226;metro dos cardiomi&#243;citos e a fra&#231;&#227;o de col&#225;geno foram avaliados por meio de an&#225;lise histol&#243;gica. Os dados foram comparados por ANOVA de um caminho com post hoc de Duncan. O n&#237;vel de signific&#226;ncia foi considerado p &lt; 0,05. RESULTADOS: Destacando FE e remodela&#231;&#227;o card&#237;aca, verificamos que, isoladamente, T, M e C apresentaram melhora das vari&#225;veis. Na associa&#231;&#227;o, ap&#243;s o per&#237;odo de interven&#231;&#227;o, observamos aumento da toler&#226;ncia ao esfor&#231;o em MT e CT (43,0% e 33,0%, respectivamente). Houve tamb&#233;m redu&#231;&#227;o do di&#226;metro dos cardiomi&#243;citos (10,0% e 9,0%, respectivamente) e da fra&#231;&#227;o de col&#225;geno (52,0% e 63,0%), ap&#243;s a interven&#231;&#227;o. Por&#233;m, somente CT melhorou significantemente a FE. CONCLUS&#195;O: A associa&#231;&#227;o do TF &#224;s terapias com M ou C proporcionou benef&#237;cios sobre a fun&#231;&#227;o e remodela&#231;&#227;o card&#237;aca em camundongos com IC.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>treinamento</kwd>
        <kwd>exerc&#237;cio</kwd>
        <kwd>sistema nervoso simp&#225;tico</kwd>
        <kwd>beta-bloqueadores</kwd>
        <kwd>camundongos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>30</day>
        <month>07</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGOS ORIGINAIS </p>
    <p> FISIOLOGIA</p>
    <p>Associa&#231;&#227;o de betabloqueadores e treinamento f&#237;sico na insufici&#234;ncia card&#237;aca de camundongos</p>
    <p>
      <bold>Andr&#233;a Somolanji Vanzelli<sup>I,II</sup>; Alessandra Medeiros<sup>III</sup>; Raquel de Assis Sirvente<sup>II</sup>; Vera Maria Cury Salemi<sup>II</sup>; Charles Mady<sup>II</sup>; Patricia Chakur Brum<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Escola de Educa&#231;&#227;o F&#237;sica da Universidade de S&#227;o Paulo </p>
    <p><sup>II</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (FMUSP) </p>
    <p><sup>III</sup>Universidade Federal de S&#227;o Paulo (UNIFESP), S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> O tratamento da insufici&#234;ncia card&#237;aca (IC) conta atualmente com diversos tipos de interven&#231;&#245;es. Dentre elas, destacam-se a terapia com betabloqueadores (BB) e o treinamento f&#237;sico (TF). Contudo, os efeitos da associa&#231;&#227;o dessas terapias s&#227;o pouco estudados. </p>
    <p><bold>OBJETIVO:</bold> Verificar os efeitos do tratamento com BB, metoprolol (M) e carvedilol (C) associados ao TF na IC em camundongos. </p>
    <p><bold>M&#201;TODOS:</bold> Utilizamos modelo gen&#233;tico de IC induzida em camundongos por hiperatividade simp&#225;tica. Inicialmente, dividimos os animais com IC em: sedent&#225;rios (S); treinados (T); tratados com M (138 mg/kg) (M) ou C (65 mg/kg) (C). Na segunda parte, dividimos os grupos em S; treinado e tratado com M (MT) e treinado e tratado com C (CT). O TF consistiu em treinamento aer&#243;bico em esteira por 8 semanas. A toler&#226;ncia ao esfor&#231;o foi avaliada por teste progressivo m&#225;ximo e a fra&#231;&#227;o de encurtamento foi avaliada (FE) por ecocardiografia. O di&#226;metro dos cardiomi&#243;citos e a fra&#231;&#227;o de col&#225;geno foram avaliados por meio de an&#225;lise histol&#243;gica. Os dados foram comparados por ANOVA de um caminho com <italic>post hoc</italic> de Duncan. O n&#237;vel de signific&#226;ncia foi considerado p <underline>&lt;</underline> 0,05. </p>
    <p><bold>RESULTADOS:</bold> Destacando FE e remodela&#231;&#227;o card&#237;aca, verificamos que, isoladamente, T, M e C apresentaram melhora das vari&#225;veis. Na associa&#231;&#227;o, ap&#243;s o per&#237;odo de interven&#231;&#227;o, observamos aumento da toler&#226;ncia ao esfor&#231;o em MT e CT (43,0% e 33,0%, respectivamente). Houve tamb&#233;m redu&#231;&#227;o do di&#226;metro dos cardiomi&#243;citos (10,0% e 9,0%, respectivamente) e da fra&#231;&#227;o de col&#225;geno (52,0% e 63,0%), ap&#243;s a interven&#231;&#227;o. Por&#233;m, somente CT melhorou significantemente a FE. </p>
    <p><bold>CONCLUS&#195;O:</bold> A associa&#231;&#227;o do TF &#224;s terapias com M ou C proporcionou benef&#237;cios sobre a fun&#231;&#227;o e remodela&#231;&#227;o card&#237;aca em camundongos com IC. </p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, treinamento, exerc&#237;cio, sistema nervoso simp&#225;tico, beta-bloqueadores, camundongos.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca &#233; a via final comum para diversas doen&#231;as cardiovasculares, constituindo-se em uma s&#237;ndrome caracterizada por sinais e sintomas relacionados &#224; perfus&#227;o tecidual inadequada<sup>1</sup> e ao excesso de catecolaminas<sup>2</sup>. De acordo com a vis&#227;o hemodin&#226;mica, a s&#237;ndrome da insufici&#234;ncia card&#237;aca est&#225; associada a um baixo d&#233;bito card&#237;aco, com consequente baixo fluxo renal, levando &#224; reten&#231;&#227;o de s&#243;dio e &#225;gua e ao surgimento de edemas perif&#233;rico e pulmonar<sup>3</sup>. Outra caracter&#237;stica comum da insufici&#234;ncia card&#237;aca &#233; a remodela&#231;&#227;o card&#237;aca associada &#224; perda de cardiomi&#243;citos e ao aumento da fra&#231;&#227;o de col&#225;geno<sup>4,5</sup>.</p>
    <p>Nas duas &#250;ltimas d&#233;cadas, houve not&#243;rio progresso no tratamento da IC. A introdu&#231;&#227;o dos agentes betabloqueadores e dos inibidores do sistema renina-angiotensina-aldosterona provocou uma n&#237;tida mudan&#231;a no comportamento cl&#237;nico dos pacientes, bem como trouxe a perspectiva de &#237;ndices de sobrevida mais promissores. Ensaios cl&#237;nicos mostraram redu&#231;&#245;es relevantes da mortalidade como nunca apresentado anteriormente no tratamento da IC<sup>6-10</sup>.</p>
    <p>As possibilidades de otimiza&#231;&#227;o terap&#234;utica e cl&#237;nica ampliam-se quando medidas n&#227;o farmacol&#243;gicas, tais como dieta e atividade f&#237;sica regular, s&#227;o associadas ao tratamento farmacol&#243;gico convencional. De fato, o treinamento f&#237;sico aer&#243;bico tem sido cada vez mais adotado e seus benef&#237;cios incluem melhora na qualidade de vida do paciente e toler&#226;ncia a esfor&#231;os f&#237;sicos, al&#233;m da redu&#231;&#227;o na hiperatividade de sistemas neuro-humorais que est&#225; diretamente relacionada &#224; melhora na sobrevida do paciente<sup>11</sup> e no balan&#231;o auton&#244;mico<sup>12-14</sup>.</p>
    <p>Em estudos anteriores do nosso laborat&#243;rio, demonstramos que a terapia com o betabloqueador carvedilol reduziu significantemente a atividade nervosa simp&#225;tica em pacientes com IC<sup>15</sup>, e, mais recentemente, demonstramos que a terapia n&#227;o farmacol&#243;gica com o treinamento f&#237;sico aer&#243;bio provocou redu&#231;&#227;o adicional na atividade simp&#225;tica de pacientes com IC que j&#225; estavam sob terapia com o betabloqueador carvedilol<sup>16</sup>. Esses resultados sugerem que a associa&#231;&#227;o do treinamento f&#237;sico aer&#243;bico ao betabloqueador &#233; capaz de otimizar a redu&#231;&#227;o na hiperatividade de sistemas neuro-humorais.</p>
    <p>No presente estudo, utilizamos um modelo gen&#233;tico de IC induzida por hiperatividade simp&#225;tica em camundongos para estudar o efeito da associa&#231;&#227;o dos betabloqueadores metoprolol ou carvedilol ao treinamento f&#237;sico aer&#243;bico sobre a fun&#231;&#227;o e a estrutura card&#237;acas.</p>
    <p>
      <bold>Material e m&#233;todos</bold>
    </p>
    <p>
      <bold>Amostra</bold>
    </p>
    <p>Foram utilizados camundongos machos da linhagem C57/BL6 com inativa&#231;&#227;o g&#234;nica dos receptores &#945;<sub>2A</sub>/&#945;<sub>2C</sub> adren&#233;rgicos (&#945;/&#945;<sub>2C</sub>ARKO), na faixa et&#225;ria compreendida entre os 5-7 meses de vida, provenientes do Biot&#233;rio da Escola de Educa&#231;&#227;o F&#237;sica e Esporte da USP (n = 35). Esses camundongos desenvolvem sinais cl&#237;nicos de IC como edema pulmonar associado &#224; disfun&#231;&#227;o ventricular grave aos 7 meses de idade, quando a taxa de mortalidade &#233; de 50,0%<sup>12,17</sup>. A inativa&#231;&#227;o g&#234;nica dos receptores &#945;<sub>2A</sub> e &#945;<sub>2C</sub> adren&#233;rgicos leva &#224; eleva&#231;&#227;o na libera&#231;&#227;o de noradrenalina circulante<sup>18,19</sup>, sendo, portanto, a IC observada neste modelo devido &#224; hiperatividade do sistema nervoso simp&#225;tico.</p>
    <p>O presente estudo foi aprovado no Comit&#234; de &#201;tica da Faculdade de Medicina da USP (897/06).</p>
    <p>Numa primeira etapa do nosso trabalho, com o intuito de avaliar o efeito das terapias isoladas sobre as vari&#225;veis analisadas, dividimos os animais aleatoriamente em &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO sedent&#225;rio (S); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO treinado (T); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO tratado com metoprolol (M) &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO tratado com carvedilol (C). Ap&#243;s conhecermos o efeito isolado dos tratamentos, avaliamos o efeito das terapias associadas e, para isso, os animais foram subdivididos aleatoriamente nos seguintes subgrupos: &#945;<sub>2A/</sub>&#945;<sub>2C</sub>ARKO sedent&#225;rio (S); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO treinado e tratado com metoprolol (MT) e grupo &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO treinado e tratado com carvedilol (CT).</p>
    <p>Camundongos controle sem IC (WT) s&#227;o apresentados nas figuras do estudo com uma linha tracejada para que se observe o valor esperado em grupo controle sem insufici&#234;ncia card&#237;aca.</p>
    <p>Os tratamentos foram realizados via gavagem e as doses utilizadas foram anteriormente testadas a fim de se ajustar e de se obter doses equipotentes na redu&#231;&#227;o da frequ&#234;ncia card&#237;aca dos animais, 135 mg/kg e 68 mg/kg para metoprolol e carvedilol, respectivamente<sup>20,21</sup>.</p>
    <p>O peso corporal foi acompanhado semanalmente em balan&#231;a semianal&#237;tica (Gehaka, BG 400 - S&#227;o Paulo, SP, Brasil)</p>
    <p>
      <bold>Capacidade m&#225;xima de realiza&#231;&#227;o de exerc&#237;cio f&#237;sico</bold>
    </p>
    <p>A intoler&#226;ncia &#224; realiza&#231;&#227;o de esfor&#231;os foi estimada nos grupos estudados por meio da quantifica&#231;&#227;o da capacidade m&#225;xima de realiza&#231;&#227;o do exerc&#237;cio f&#237;sico (tempo total do teste em segundos) atrav&#233;s de um teste progressivo escalonado at&#233; a exaust&#227;o, constatada quando o animal n&#227;o conseguia manter a corrida, em esteira rolante (confeccionada por servi&#231;o aut&#244;nomo da Universidade Federal de S&#227;o Carlos, S&#227;o Carlos, SP, Brasil) com velocidade inicial de 3 m/min e aumento de 3 m/min a cada 3 min<sup>12</sup>.</p>
    <p>
      <bold>Protocolo de treinamento f&#237;sico aer&#243;bio</bold>
    </p>
    <p>Os grupos de animais treinados foram submetidos a um programa de treinamento f&#237;sico aer&#243;bico em esteira rolante durante 8 semanas (dos 5 aos 7 meses de idade). As sess&#245;es de exerc&#237;cio foram realizadas 5 vezes por semana, com dura&#231;&#227;o de 60 minutos por sess&#227;o e intensidade de 60,0% da velocidade m&#225;xima verificada no teste progressivo at&#233; a exaust&#227;o, que, conforme observamos em estudo anterior, corresponde ao m&#225;ximo estado est&#225;vel do lactato<sup>22</sup>, ou seja, corresponde &#224; m&#225;xima intensidade de exerc&#237;cio f&#237;sico onde h&#225; um equil&#237;brio entre a produ&#231;&#227;o e a remo&#231;&#227;o do lactato sangu&#237;neo durante o exerc&#237;cio prolongado.</p>
    <p>
      <bold>Registro indireto da press&#227;o arterial e frequ&#234;ncia card&#237;aca</bold>
    </p>
    <p>Foi realizada a medida indireta da press&#227;o arterial pelo m&#233;todo de pletismografia de cauda ao longo das 8 semanas de interven&#231;&#227;o (<italic>Kent Scientific</italic>, CODA - Torrington, CT, EUA) e, atrav&#233;s dos pulsos de press&#227;o registrados, calculou-se a frequ&#234;ncia card&#237;aca dos camundongos, conforme j&#225; realizado em trabalhos anteriores<sup>13,20,21,23</sup>.</p>
    <p>
      <bold>Avalia&#231;&#227;o ecocardiogr&#225;fica</bold>
    </p>
    <p>O exame ecocardiogr&#225;fico transtor&#225;cico foi realizado antes e ap&#243;s o per&#237;odo de interven&#231;&#227;o em todos os grupos estudados. O exame ecocardiogr&#225;fico foi realizado com os animais anestesiados por meio do anest&#233;sico halotano 1,0%, com fluxo 1 l/min de O<sub>2</sub> misturado ao anest&#233;sico. Foi utilizado o ecocardi&#243;grafo (Acuson Corporation, Sequoia 512 - Mountain View, CA, EUA), com transdutor de 15 MHz. As imagens foram feitas com uma frequ&#234;ncia de 14 MHz. A partir da visibiliza&#231;&#227;o do ventr&#237;culo esquerdo (corte transversal) ao n&#237;vel dos m&#250;sculos papilares, foi realizado o modo M e as medidas do di&#226;metro diast&#243;lico (DDVE) e sist&#243;lico (DSVE) do ventr&#237;culo esquerdo foram obtidas e utilizadas para o c&#225;lculo da fra&#231;&#227;o de encurtamento (FS). A f&#243;rmula utilizada foi: FS = (DDVE - DSVE) / DDVE. O ecocardiografista (R. S.) estava cego para o gen&#243;tipo e para o tipo de tratamento dos animais.</p>
    <p>
      <bold>An&#225;lises morfol&#243;gicas e morfom&#233;tricas card&#237;acas</bold>
    </p>
    <p>Ap&#243;s 48 horas de fixa&#231;&#227;o em formalina tamponada (4,0%), o ventr&#237;culo esquerdo foi submetido ao processamento histol&#243;gico habitual, com cortes de 2 micra e colora&#231;&#227;o por hematoxilina-eosina ou picross&#237;rius <italic>red</italic> para a quantifica&#231;&#227;o do di&#226;metro transverso dos cardiomi&#243;citos e fra&#231;&#227;o de col&#225;geno card&#237;aco, respectivamente. Essas medidas foram realizadas em sistema computadorizado (<italic>Leica Imaging Systems</italic> Ltda, Quantimet 500 - Cambridge, UK, Inglaterra), com aumento de 400x e 200x, respectivamente. O di&#226;metro dos cardiomi&#243;citos foi considerado a partir de uma m&#233;dia de 10 valores medidos para cada animal.</p>
    <p>A fra&#231;&#227;o do volume de col&#225;geno foi calculada pela raz&#227;o percentual da &#225;rea do tecido mioc&#225;rdico corado positivamente para as fibras col&#225;genas (quantidade absoluta de col&#225;geno) e a &#225;rea total do tecido mioc&#225;rdico em cada regi&#227;o ventricular examinada (quantidade absoluta de col&#225;geno e mi&#243;citos), campo a campo. Um n&#250;mero de 15 a 20 campos foi examinado para cada um dos animais<sup>13,20,21,23,24</sup>.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Todas as vari&#225;veis estudadas apresentaram distribui&#231;&#227;o normal, analisada pelo teste de normalidade de Shapiro-Wilk e, portanto, a an&#225;lise estat&#237;stica param&#233;trica foi utilizada. Os dados est&#227;o representados na forma de m&#233;dia &#177; erro padr&#227;o da m&#233;dia.</p>
    <p>As vari&#225;veis estudadas foram comparadas entre os grupos pela an&#225;lise de vari&#226;ncia (ANOVA) de um caminho (di&#226;metro transverso dos cardiomi&#243;citos e fra&#231;&#227;o de volume de col&#225;geno) ou um caminho com medidas repetidas (toler&#226;ncia ao esfor&#231;o, fra&#231;&#227;o de encurtamento e frequ&#234;ncia card&#237;aca). Para a mortalidade, foi utilizada a an&#225;lise de <italic>log rank</italic>. Em caso de signific&#226;ncia, foi utilizado o <italic>post hoc</italic> de Duncan. Para todas as an&#225;lises, adotou-se como n&#237;vel de signific&#226;ncia p &lt; 0,05. O <italic>software</italic> para an&#225;lise estat&#237;stica utilizado foi o <italic>Statistica</italic> Vers&#227;o 6.0.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Efeito isolado dos tratamentos (treinamento f&#237;sico, metoprolol e carvedilol sobre a toler&#226;ncia ao esfor&#231;o, fun&#231;&#227;o contr&#225;til e estrutura card&#237;aca)</bold>
    </p>
    <p>Na <xref ref-type="fig" rid="abc_nahead2210_aop09310_port_fig01">Figura 1</xref>, Painel A, que ressalta os efeitos isolados dos tratamentos na toler&#226;ncia ao esfor&#231;o, observa-se que o treinamento f&#237;sico isoladamente proporcionou melhora significante da toler&#226;ncia ao esfor&#231;o, o que n&#227;o &#233; observado nos grupos tratados com os betabloqueadores metoprolol e carvedilol. Quanto &#224; fun&#231;&#227;o ventricular, podemos notar que todos os tratamentos (TF, M ou C) melhoraram de maneira similar a fra&#231;&#227;o de encurtamento (<xref ref-type="fig" rid="abc_nahead2210_aop09310_port_fig01">Figura 1B</xref>).</p>
    <p><fig id="abc_nahead2210_aop09310_port_fig01"/>&#13;
&#160;&#13;
</p>
    <p>
      <fig id="aop09310_port_fig01abm">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf01.jpg"/></fig>
    </p>
    <p>&#13;
  <fig id="abc_nahead2210_aop09310_port_fig01xfig01cd"/><fig id="aop09310_port_fig01cdm"><graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf02.jpg"/></fig></p>
    <p>Em rela&#231;&#227;o aos efeitos na estrutura card&#237;aca, o treinamento f&#237;sico isoladamente n&#227;o proporcionou redu&#231;&#227;o significantiva do di&#226;metro transverso dos cardiomi&#243;citos, contudo, teve efeitos similares &#224;s terapias farmacol&#243;gicas na redu&#231;&#227;o da fra&#231;&#227;o de col&#225;geno card&#237;aco (<xref ref-type="fig" rid="abc_nahead2210_aop09310_port_fig01">Figuras 1C</xref> e <xref ref-type="fig" rid="abc_nahead2210_aop09310_port_fig01">1D</xref>).</p>
    <p>
      <bold>Efeito da associa&#231;&#227;o do treinamento f&#237;sico ao tratamento com os betabloqueadores</bold>
    </p>
    <p>Durante o per&#237;odo experimental, a massa corporal dos animais foi avaliada semanalmente. Observamos que os animais &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO apresentavam inicialmente uma massa corporal menor que os animais do grupo controle WT (22,2 &#177; 1,3 g <italic>vs</italic> 28,3 &#177; 2,2 g, p <underline>&lt;</underline> 0,05). Nenhum dos grupos apresentou altera&#231;&#227;o na massa durante o per&#237;odo de interven&#231;&#227;o.</p>
    <p>Avaliamos adicionalmente a curva de mortalidade durante o per&#237;odo de interven&#231;&#227;o e n&#227;o observamos diferen&#231;a significante entre os grupos (40,0% <italic>vs</italic> 20,0% e 18,0% para os grupos S, MT e CT, respectivamente, p <underline>&lt;</underline> 0,05).</p>
    <p>
      <bold>Toler&#226;ncia ao esfor&#231;o m&#225;ximo</bold>
    </p>
    <p>Na <xref ref-type="fig" rid="aop09310_port_fig02m">Figura 2</xref>, nota-se que a associa&#231;&#227;o do treinamento f&#237;sico &#224; terapia com betabloqueadores melhorou significantemente a toler&#226;ncia ao esfor&#231;o quando comparada ao grupo tratado com salina (S).</p>
    <p content-type="asset">
      <fig id="aop09310_port_fig02m">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf03.jpg"/></fig>
    </p>
    <p>Cabe ressaltar que a toler&#226;ncia ao esfor&#231;o nos animais &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO alcan&#231;ou os valores observados nos camundongos controle sem IC (<xref ref-type="fig" rid="aop09310_port_fig02m">Figura 2</xref>, linha tracejada) e os grupos treinados e tratados com os betabloqueadores metoprolol e carvedilol foram igualmente eficazes em melhorar a toler&#226;ncia ao esfor&#231;o (43,0% e 33,0% de aumento, respectivamente).</p>
    <p>
      <bold>Frequ&#234;ncia card&#237;aca e press&#227;o arterial</bold>
    </p>
    <p>Como se pode observar na <xref ref-type="fig" rid="aop09310_port_fig03m">Figura 3</xref>, os camundongos &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO apresentam taquicardia de repouso quando comparados aos camundongos controle WT (711 &#177; 3 <italic>vs</italic> 617 &#177; 24 bpm, respectivamente, p <underline>&lt;</underline> 0,05). A associa&#231;&#227;o do treinamento f&#237;sico &#224;s terapias com betabloqueadores reduziram de maneira similar a frequ&#234;ncia card&#237;aca dos camundongos &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO, a partir da 4&#170; semana de interven&#231;&#227;o, para valores semelhantes a frequ&#234;ncia observada nos camundongos controle sem IC (WT, linha tracejada). N&#227;o houve diferen&#231;a na press&#227;o arterial entre os grupos ao longo das 8 semanas de interven&#231;&#227;o (114 &#177; 7,3 mmHg na 8&#170; semana do estudo).</p>
    <p content-type="asset">
      <fig id="aop09310_port_fig03m">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf04.jpg"/></fig>
    </p>
    <p>
      <bold>Fra&#231;&#227;o de encurtamento</bold>
    </p>
    <p>Ap&#243;s o per&#237;odo de 8 semanas de interven&#231;&#227;o, apenas o grupo &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO treinado e tratado com carvedilol (CT) melhorou significantemente os valores de fra&#231;&#227;o de encurtamento (<xref ref-type="fig" rid="aop09310_port_fig04m">Figura 4</xref>) quando comparado ao grupo &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO tratado com salina (20 &#177; 0,8 <italic>vs</italic> 15 &#177; 0,4%, respectivamente, p <underline>&lt;</underline> 0,05), alcan&#231;ando valores semelhantes aos do grupo controle sem IC (WT). Interessante, a associa&#231;&#227;o do metoprolol com TF n&#227;o melhorou a fra&#231;&#227;o de encurtamento. Esse resultado foi inesperado, pois, o metoprolol e o TF, isoladamente, foram capazes de aumentar a fra&#231;&#227;o de encurtamento (<xref ref-type="fig" rid="abc_nahead2210_aop09310_port_fig01">Figura 1B</xref>).</p>
    <p content-type="asset">
      <fig id="aop09310_port_fig04m">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf05.jpg"/></fig>
    </p>
    <p>
      <bold>Di&#226;metro dos cardiomi&#243;citos e fra&#231;&#227;o de col&#225;geno</bold>
    </p>
    <p>A avalia&#231;&#227;o morfom&#233;trica card&#237;aca revelou que ambos os betabloqueadores associados ao treinamento f&#237;sico foram igualmente eficazes em reduzir significantemente o di&#226;metro transverso dos cardiomi&#243;citos (10,0% e 9,0% para os grupos treinados e tratados com metoprolol e carvedilol, respectivamente) e a fra&#231;&#227;o de col&#225;geno card&#237;aco (52,0% e 63,0% para os grupos treinados e tratados com metoprolol e carvedilol, respectivamente), o que sugere um poss&#237;vel efeito de remodela&#231;&#227;o card&#237;aca reversa associada aos efeitos combinados de ambos betabloqueadores ao treinamento f&#237;sico (<xref ref-type="fig" rid="aop09310_port_fig05m">Figura 5</xref>).</p>
    <p content-type="asset">
      <fig id="aop09310_port_fig05m">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf06.jpg"/></fig>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Nos camundongos que constituem tal modelo de cardiomiopatia induzida por hiperatividade simp&#225;tica, assim como na IC cl&#237;nica, &#233; muito comum a observa&#231;&#227;o dos sinais cl&#237;nicos, como a intoler&#226;ncia aos esfor&#231;os, o edema pulmonar, a diminui&#231;&#227;o da fun&#231;&#227;o card&#237;aca e a remodela&#231;&#227;o card&#237;aca. &#201; importante salientar que, mesmo n&#227;o se estabelecendo uma rela&#231;&#227;o causa-efeito sobre a hiperatividade simp&#225;tica na insufici&#234;ncia card&#237;aca cl&#237;nica, o desequil&#237;brio auton&#244;mico tem importante papel no progn&#243;stico do paciente, o que torna o modelo de camundongos utilizado no presente estudo mais interessante, pois, possibilita estudar o efeito direto da hiperatividade simp&#225;tica na IC.</p>
    <p>Feito esse adendo, os principais resultados deste estudo em camundongos com IC induzida por hiperatividade simp&#225;tica foram que:</p>
    <p>1) Ambos metoprolol e carvedilol, quando associados ao treinamento f&#237;sico, melhoraram de maneira similar &#224; toler&#226;ncia aos esfor&#231;os e reduziram de maneira equipotente a taquicardia de repouso;</p>
    <p>2) O treinamento f&#237;sico e as terapias farmacol&#243;gicas isoladamente, al&#233;m da associa&#231;&#227;o do carvedilol ao treinamento f&#237;sico, melhoraram significantemente a fra&#231;&#227;o de encurtamento;</p>
    <p>3) Ambos metoprolol e carvedilol associados ao treinamento f&#237;sico reduziram similarmente a fra&#231;&#227;o de volume de col&#225;geno card&#237;aco e o di&#226;metro transverso dos cardiomi&#243;citos.</p>
    <p>Anteriormente, mostramos que o treinamento f&#237;sico melhora a fra&#231;&#227;o de encurtamento na insufici&#234;ncia card&#237;aca por melhora no transiente de c&#225;lcio e do perfil de express&#227;o das prote&#237;nas que regulam o fluxo de Ca<sup>2+</sup> intracelular<sup>13,23</sup>. Al&#233;m disso, mostramos tamb&#233;m que o carvedilol &#233; mais eficaz em reduzir o estresse oxidativo do que em melhorar o transiente de Ca<sup>2+</sup> card&#237;aco<sup>20</sup>. Portanto, essa combina&#231;&#227;o pode potencializar os efeitos ben&#233;ficos de ambas as terapias sobre a fun&#231;&#227;o card&#237;aca. J&#225; a associa&#231;&#227;o do metoprolol com o treinamento f&#237;sico parece ser menos pronunciada, muito provavelmente em virtude do metoprolol tamb&#233;m ter seu efeito card&#237;aco semelhante ao do TF, ou seja, mais associado ao transiente de c&#225;lcio e n&#227;o &#224; redu&#231;&#227;o do estresse oxidativo<sup>20</sup>.</p>
    <p>Embora o carvedilol e o metoprolol tenham tido efeito diferenciado na associa&#231;&#227;o com o treinamento f&#237;sico sobre a contratilidade ventricular, ambos, quando associados ao treinamento f&#237;sico, foram igualmente eficazes em melhorar a toler&#226;ncia aos esfor&#231;os.</p>
    <p>O aumento da toler&#226;ncia &#224; realiza&#231;&#227;o de esfor&#231;o f&#237;sico n&#227;o depende exclusivamente da melhora da fun&#231;&#227;o card&#237;aca, mas da associa&#231;&#227;o de um melhor desempenho card&#237;aco com adapta&#231;&#245;es ben&#233;ficas em alvos n&#227;o card&#237;acos. Isso pode incluir a resposta vasodilatadora no endot&#233;lio vascular, na distribui&#231;&#227;o do d&#233;bito card&#237;aco e na resposta ventilat&#243;ria<sup>25</sup>, assim como modifica&#231;&#245;es na musculatura esquel&#233;tica.</p>
    <p>An&#225;lises da estrutura muscular esquel&#233;tica, realizadas no mesmo modelo gen&#233;tico utilizado neste estudo, com camundongos &#945;<sub>2A</sub>/&#945;<sub>2C</sub>-ARKO, aos 7 meses de idade, por meio da t&#233;cnica de histoqu&#237;mica para ATPase mios&#237;nica, mostraram diminui&#231;&#227;o da &#225;rea seccional das fibras musculares, altera&#231;&#227;o fenot&#237;pica das fibras do tipo I para fibras do tipo II e rarefa&#231;&#227;o capilar. As altera&#231;&#245;es descritas parecem ainda estar acompanhadas pela mudan&#231;a do perfil metab&#243;lico, com redu&#231;&#227;o da atividade de enzimas oxidativas<sup>26</sup>. Tal fato pode estar associado &#224; redu&#231;&#227;o progressiva da toler&#226;ncia ao esfor&#231;o, observada no presente estudo.</p>
    <p>No que diz respeito aos efeitos dos betabloqueadores na toler&#226;ncia ao esfor&#231;o, v&#225;rios estudos na literatura examinaram seu uso em portadores de diversas cardiopatias<sup>27,28</sup>. Os ensaios cl&#237;nicos que perduraram por mais de um m&#234;s observaram melhoras significativas na fun&#231;&#227;o ventricular, mas muito sutis na toler&#226;ncia ao esfor&#231;o<sup>27,28</sup>. Portanto, o treinamento f&#237;sico parece exercer papel fundamental na melhora da toler&#226;ncia &#224; realiza&#231;&#227;o de esfor&#231;o na insufici&#234;ncia card&#237;aca desses camundongos, corroborando outros estudos que mostram o mesmo efeito<sup>29,30</sup>.</p>
    <p>De modo parecido ao resultado da toler&#226;ncia &#224; realiza&#231;&#227;o de esfor&#231;o, observamos comportamentos semelhantes na redu&#231;&#227;o da frequ&#234;ncia card&#237;aca nos grupos metoprolol e carvedilol associados ao treinamento f&#237;sico. Ambos tiveram efeito equipotente sobre a FC, reduzindo-a para os valores semelhantes aos observados nos camundongos WT (linha tracejada) e, portanto, mostrando a efic&#225;cia do tratamento com os dois betabloqueadores na diminui&#231;&#227;o da taquicardia apresentada neste modelo de cardiomiopatia, que est&#225; relacionada a um aumento da atividade do sistema nervoso simp&#225;tico. Tais efeitos bradic&#225;rdicos, portanto, podem sugerir uma melhora no balan&#231;o auton&#244;mico nesses camundongos, que, por sua vez, est&#225; relacionada a uma melhora do progn&#243;stico e da sobrevida na insufici&#234;ncia card&#237;aca<sup>16,31</sup>. Al&#233;m disso, os valores elevados da frequ&#234;ncia card&#237;aca tamb&#233;m emergem como preditores independentes de mortalidade na popula&#231;&#227;o em geral<sup>32,33</sup>.</p>
    <p>Aliada &#224;s altera&#231;&#245;es na fun&#231;&#227;o ventricular, nossos resultados tamb&#233;m sugerem a remodela&#231;&#227;o card&#237;aca nos camundongos com insufici&#234;ncia card&#237;aca (<xref ref-type="fig" rid="aop09310_port_fig04m">Figura 4</xref>). Ambos os betabloqueadores em associa&#231;&#227;o com o treinamento f&#237;sico apresentaram efeitos ben&#233;ficos na estrutura card&#237;aca, prevenindo a hipertrofia dos cardiomi&#243;citos e o aumento do col&#225;geno card&#237;aco.</p>
    <p>De fato, o treinamento f&#237;sico tem efeito na remodela&#231;&#227;o reversa associada &#224; redu&#231;&#227;o na via de sinaliza&#231;&#227;o da calcineurina, que est&#225; relacionada &#224; hipertrofia patol&#243;gica<sup>34</sup> ou ativa&#231;&#227;o da via da Akt associada &#224; hipertrofia fisiol&#243;gica<sup>35</sup>. Portanto, a associa&#231;&#227;o do TF aos betabloqueadores &#233; uma conduta a ser adotada, uma vez que a remodela&#231;&#227;o est&#225; altamente relacionada ao &#243;bito em pacientes com IC<sup>36-38</sup>.</p>
    <p>Outros efeitos do treinamento f&#237;sico, minimizando o processo de fal&#234;ncia do mioc&#225;rdio, t&#234;m sido recentemente mostrados e podem estar associados, dentre outros fatores, &#224; redu&#231;&#227;o de prote&#237;nas associadas &#224; fibrose e &#224; remodela&#231;&#227;o card&#237;aca<sup>39,40</sup>.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>A associa&#231;&#227;o de treinamento f&#237;sico &#224;s terapias com metoprolol ou carvedilol melhorou de modo semelhante a toler&#226;ncia ao esfor&#231;o e melhorou tamb&#233;m a estrutura card&#237;aca dos camundongos com IC induzida por hiperatividade simp&#225;tica. No entanto, somente o carvedilol quando associado ao TF melhorou a contratilidade.</p>
    <p>
      <bold>Agradecimentos</bold>
    </p>
    <p>&#192; Faculdade de Medicina e &#224; Escola de Educa&#231;&#227;o F&#237;sica e Esporte da Universidade de S&#227;o Paulo. &#192; FAPESP pelo financiamento do estudo (06/56123-0, 05/59740-7). P. C. B. tem bolsa pesquisador n&#237;vel ID do CNPq (301519/2008-0).</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo foi financiado pela FAPESP.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Andr&#233;a Somolanji Vanzelli pela Faculdade de Medicina da Universidade de S&#227;o Paulo.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Andr&#233;a Somolanji Vanzelli </p>
        <p> Rua Arnaldo Sim&#245;es Pinto, 166 - Vila Bonilha </p>
        <p> 02917-110 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="vanzelli@usp.br">vanzelli@usp.br</email>, </p>
        <p>
          <email xlink:href="andreasvanzelli@gmail.com">andreasvanzelli@gmail.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 29/09/09; revisado recebido em 11/02/10; aceito em 16/03/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1.  Adamopoulos S, Parissis JT, Kremastinos DT. New aspects for the role of physical  training in the management of patients with chronic heart failure. Int J Cardiol.  2003; 90 (1): 1-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>New aspects for the role of physical training in the management of patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1</fpage>
          <lpage>14</lpage>
          <issue>1</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parissis</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Kremastinos</surname>
              <given-names>DT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2.  Opie LH, Walpoth B, Barsacchi R. Calcium and catecholamines: relevance to cardiomyopathies  and significance in therapeutic strategies. J Mol Cell Cardiol. 1985; 17 (Suppl  2): 21-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Calcium and catecholamines: relevance to cardiomyopathies and significance in therapeutic strategies</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>21</fpage>
          <lpage>34</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Opie</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Walpoth</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Barsacchi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3.  Katz AM. Evolving concepts of heart failure: cooling furnace, malfunctioning pump,  enlarging muscle--Part I. J Card Fail. 1997; 3 (4): 319-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evolving concepts of heart failure: cooling furnace, malfunctioning pump, enlarging muscle--Part I</article-title>
          <source>J Card Fail</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>319</fpage>
          <lpage>34</lpage>
          <issue>4</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4.  Grimm D, Huber M, Jabusch HC, Shakibaei M, Fredersdorf S, Paul M, et al. Extracellular  matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure  overload: effects of beta-receptor blockade. J Mol Cell Cardiol. 2001; 33 (3):  487-501.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>487</fpage>
          <lpage>501</lpage>
          <issue>3</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grimm</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jabusch</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Shakibaei</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fredersdorf</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5.  Kunst G, Kress KR, Gruen M, Uttenweiler D, Gautel M, Fink RH. Myosin binding protein  C, a phosphorylation-dependent force regulator in muscle that controls the attachment  of myosin heads by its interaction with myosin S2. Circ Res. 2000; 86 (1): 51-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2</article-title>
          <source>Circ Res</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>51</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kunst</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kress</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Gruen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uttenweiler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gautel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fink</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6.  Rationale, design, and organization of the Metoprolol CR/XL Randomized Intervention  Trial in Heart Failure (MERIT-HF). The International Steering Committee. Am J  Cardiol. 1997; 80 (9B): 54J-8J.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The International Steering Committee</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>54J</fpage>
          <lpage>8J</lpage>
          <issue>9B</issue>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rationale</surname>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7.  Carvedilol saves lives--new data from landmark trials prove survival benefits  in heart failure and post myocardial infarction. Cardiovasc J S Afr. 2001; 12  (2): 122-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Carvedilol saves lives--new data from landmark trials prove survival benefits in heart failure and post myocardial infarction</article-title>
          <source>Cardiovasc J S Afr</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>122</fpage>
          <lpage>3</lpage>
          <issue>2</issue>
          <volume>12</volume>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8.  Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, et al.  A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy.  Am J Cardiol. 1985; 55 (4): 471-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>471</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lutz</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sorensen</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Yanowitz</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Menlove</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9.  Cesario DA, Fonarow GC. Beta-blocker therapy for heart failure: the standard of  care. Rev Cardiovasc Med. 2002; 3 (1): 14-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Beta-blocker therapy for heart failure: the standard of care</article-title>
          <source>Rev Cardiovasc Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>14</fpage>
          <lpage>21</lpage>
          <issue>1</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cesario</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10.  Metra M, Nodari S, Bordonali T, Milani P, Lombardi C, Bugatti S, et al. Bisoprolol  in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology  and trial results. Ther Clin Risk Manag. 2007; 3 (4): 569-78.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results</article-title>
          <source>Ther Clin Risk Manag</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>569</fpage>
          <lpage>78</lpage>
          <issue>4</issue>
          <volume>3</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Metra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nodari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bordonali</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Milani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bugatti</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11.  Pereira MG, Ferreira JC, Bueno CR Jr, Mattos KC, Rosa KT, Irigoyen MC, et al.  Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction  in a genetic model of sympathetic hyperactivity-induced heart failure in mice.  Eur J Appl Physiol. 2009; 105 (6): 843-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice</article-title>
          <source>Eur J Appl Physiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>843</fpage>
          <lpage>50</lpage>
          <issue>6</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bueno Jr</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Irigoyen</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12.  Brum PC, Kosek J, Patterson A, Bernstein D, Kobilka B. Abnormal cardiac function  associated with sympathetic nervous system hyperactivity in mice. Am J Physiol  Heart Circ Physiol. 2002; 283 (5): H1838-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>H1838</fpage>
          <lpage>45</lpage>
          <issue>5</issue>
          <volume>283</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brum</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Kosek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kobilka</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13.  Medeiros A, Rolim NP, Oliveira RS, Rosa KT, Mattos KC, Casarini DE, et al. Exercise  training delays cardiac dysfunction and prevents calcium handling abnormalities  in sympathetic hyperactivity-induced heart failure mice. J Appl Physiol. 2008;  104 (1): 103-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training delays cardiac dysfunction and prevents calcium handling abnormalities in sympathetic hyperactivity-induced heart failure mice</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>103</fpage>
          <lpage>9</lpage>
          <issue>1</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Medeiros</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rolim</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Casarini</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14.  Stickland MK, Miller JD. The best medicine: exercise training normalizes chemosensitivity  and sympathoexcitation in heart failure. J Appl Physiol. 2008; 105 (3): 779-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The best medicine: exercise training normalizes chemosensitivity and sympathoexcitation in heart failure</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>779</fpage>
          <lpage>81</lpage>
          <issue>3</issue>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stickland</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15.  De Matos LD, Gardenghi G, Rondon MU, Soufen HN, Tirone AP, Barretto AC, et al.  Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity  in heart failure patients. J Card Fail. 2004;10 (6): 496-502.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>496</fpage>
          <lpage>502</lpage>
          <issue>6</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Matos</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Gardenghi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rondon</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Soufen</surname>
              <given-names>HN</given-names>
            </name>
            <name>
              <surname>Tirone</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16.  Fraga R, Franco FG, Roveda F, de Matos LN, Braga AM, Rondon MU, et al. Exercise  training reduces sympathetic nerve activity in heart failure patients treated  with carvedilol. Eur J Heart Fail. 2007; 9 (6-7): 630-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>630</fpage>
          <lpage>6</lpage>
          <issue>6-7</issue>
          <volume>9</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fraga</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Roveda</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Matos</surname>
              <given-names>LN</given-names>
            </name>
            <name>
              <surname>Braga</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Rondon</surname>
              <given-names>MU</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17.  Ferreira JC, Bacurau AV, Evangelista FS, Coelho MA, Oliveira EM, Casarini DE,  et al. The role of local and systemic renin angiotensin system activation in a  genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J  Physiol Regul Integr Comp Physiol. 2008; 294 (1): R26-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice</article-title>
          <source>Am J Physiol Regul Integr Comp Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>R26</fpage>
          <lpage>32</lpage>
          <issue>1</issue>
          <volume>294</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bacurau</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Evangelista</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Casarini</surname>
              <given-names>DE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18.  Davies MF, Tsui JY, Flannery JA, Li X, DeLorey TM, Hoffman BB. Augmentation of  the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical  changes associated with enhanced fear memory. Brain Res. 2003;986 (1-2): 157-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Augmentation of the noradrenergic system in alpha-2 adrenergic receptor deficient mice: anatomical changes associated with enhanced fear memory</article-title>
          <source>Brain Res</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>157</fpage>
          <lpage>65</lpage>
          <issue>1-2</issue>
          <volume>986</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Tsui</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Flannery</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>DeLorey</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19.  Kurnik D, Muszkat M, Friedman EA, Sofowora GG, Diedrich A, Xie HG, et al. Effect  of the alpha2C-adrenoreceptor deletion322-325 variant on sympathetic activity  and cardiovascular measures in healthy subjects. J Hypertens. 2007; 25 (4): 763-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of the alpha2C-adrenoreceptor deletion322-325 variant on sympathetic activity and cardiovascular measures in healthy subjects</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>763</fpage>
          <lpage>71</lpage>
          <issue>4</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kurnik</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Muszkat</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Sofowora</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Diedrich</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Xie</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20.  Bartholomeu JB, Vanzelli AS, Rolim NP, Ferreira JC, Bechara LR, Tanaka LY, et  al. Intracellular mechanisms of specific beta-adrenoceptor antagonists involved  in improved cardiac function and survival in a genetic model of heart failure.  J Mol Cell Cardiol. 2008; 45 (2): 240-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>240</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>45</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bartholomeu</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Vanzelli</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Rolim</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bechara</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>LY</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21.  Medeiros A, Vanzelli AS, Rosa KT, Irigoyen MC, Brum PC. Effect of exercise training  and carvedilol treatment on cardiac function and structure in mice with sympathetic  hyperactivity-induced heart failure. Braz J Med Biol Res. 2008; 41 (9): 812-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure</article-title>
          <source>Braz J Med Biol Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>812</fpage>
          <lpage>7</lpage>
          <issue>9</issue>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Medeiros</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vanzelli</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Irigoyen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Brum</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22.  Ferreira JC, Rolim NP, Bartholomeu JB, Gobatto CA, Kokubun E, Brum PC. Maximal  lactate steady state in running mice: effect of exercise training. Clin Exp Pharmacol  Physiol. 2007; 34 (8): 760-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Maximal lactate steady state in running mice: effect of exercise training</article-title>
          <source>Clin Exp Pharmacol Physiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>760</fpage>
          <lpage>5</lpage>
          <issue>8</issue>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Rolim</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Bartholomeu</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Gobatto</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kokubun</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brum</surname>
              <given-names>PC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23.  Rolim NP, Medeiros A, Rosa KT, Mattos KC, Irigoyen MC, Krieger EM, et al. Exercise  training improves the net balance of cardiac Ca2+ handling protein expression  in heart failure. Physiol Genomics. 2007; 29 (3): 246-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training improves the net balance of cardiac Ca2+ handling protein expression in heart failure</article-title>
          <source>Physiol Genomics</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>246</fpage>
          <lpage>52</lpage>
          <issue>3</issue>
          <volume>29</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rolim</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Irigoyen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24.  Xu R, Lin F, Zhang S, Chen X, Hu S, Zheng Z. Signal pathways involved in reverse  remodeling of the hypertrophic rat heart after pressure unloading. Int J Cardiol.  2009. [Epub ahead of print]</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Signal pathways involved in reverse remodeling of the hypertrophic rat heart after pressure unloading</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25.  Pina IL, Daoud S. Exercise and heart failure. Minerva Cardioangiol. 2004; 52 (6):  537-46.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise and heart failure</article-title>
          <source>Minerva Cardioangiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>537</fpage>
          <lpage>46</lpage>
          <issue>6</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pina</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Daoud</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26.  Bacurau AV, Jardim MA, Ferreira JC, Bechara LR, Bueno CR Jr, Alba-Loureiro TC,  et al. Sympathetic hyperactivity differentially affects skeletal muscle mass in  developing heart failure: role of exercise training. J Appl Physiol. 2009; 106  (5): 1631-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sympathetic hyperactivity differentially affects skeletal muscle mass in developing heart failure: role of exercise training</article-title>
          <source>J Appl Physiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1631</fpage>
          <lpage>40</lpage>
          <issue>5</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bacurau</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Jardim</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bechara</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Bueno Jr</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Alba-Loureiro</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27.  Al-Nasser F, Yousufuddin M, Al-Nozha F, Anker SD, Coats AJ, Piepoli MF, et al.  Effect of carvedilol on exercise tolerance in patients with chronic heart failure  and a restrictive left ventricular filling pattern. Am J Cardiol. 2003; 91 (10):  1281-3.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1281</fpage>
          <lpage>3</lpage>
          <issue>10</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Al-Nasser</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yousufuddin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Al-Nozha</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Piepoli</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28.  Gullestad L, Dolva LO, Soyland E, Kjekshus J. Difference between beta-1-selective  and non-selective beta-blockade during continuous and intermittent exercise. Clin  Physiol. 1988; 8 (5): 487-99.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Difference between beta-1-selective and non-selective beta-blockade during continuous and intermittent exercise</article-title>
          <source>Clin Physiol</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>487</fpage>
          <lpage>99</lpage>
          <issue>5</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dolva</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Soyland</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kjekshus</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29.  Experience from controlled trials of physical training in chronic heart failure.  Protocol and patient factors in effectiveness in the improvement in exercise tolerance.  European Heart Failure Training Group. Eur Heart J. 1998; 19 (3): 466-75.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Experience from controlled trials of physical training in chronic heart failure: Protocol and patient factors in effectiveness in the improvement in exercise tolerance. European Heart Failure Training Group</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>466</fpage>
          <lpage>75</lpage>
          <issue>3</issue>
          <volume>19</volume>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30.  Tyni-Lenne R, Gordon A, Europe E, Jansson E, Sylven C. Exercise-based rehabilitation  improves skeletal muscle capacity, exercise tolerance, and quality of life in  both women and men with chronic heart failure. J Card Fail. 1998; 4 (1): 9-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise-based rehabilitation improves skeletal muscle capacity, exercise tolerance, and quality of life in both women and men with chronic heart failure</article-title>
          <source>J Card Fail</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>9</fpage>
          <lpage>17</lpage>
          <issue>1</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tyni-Lenne</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Europe</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jansson</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sylven</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31.  Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, et al. Increased  muscle sympathetic nerve activity predicts mortality in heart failure patients.  Int J Cardiol. 2009; 135 (3): 302-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Increased muscle sympathetic nerve activity predicts mortality in heart failure patients</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>302</fpage>
          <lpage>7</lpage>
          <issue>3</issue>
          <volume>135</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Munhoz</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Rondon</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Franco</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Trombetta</surname>
              <given-names>IC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32.  Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, et al. Heart rate  as a prognostic factor for coronary heart disease and mortality: findings in three  Chicago epidemiologic studies. Am J Epidemiol. 1980; 112 (6): 736-49.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies</article-title>
          <source>Am J Epidemiol</source>
          <date>
            <year>1980</year>
          </date>
          <fpage>736</fpage>
          <lpage>49</lpage>
          <issue>6</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dyer</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Persky</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Stamler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Shekelle</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Berkson</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33.  Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular  mortality: the Framingham Study. Am Heart J. 1987; 113 (6): 1489-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart rate and cardiovascular mortality: the Framingham Study</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>1489</fpage>
          <lpage>94</lpage>
          <issue>6</issue>
          <volume>113</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kannel</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Kannel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Paffenbarger Jr</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Cupples</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34.  Oliveira RS, Ferreira JC, Gomes ER, Paixao NA, Rolim NP, Medeiros A, et al. Cardiac  anti-remodelling effect of aerobic training is associated with a reduction in  the calcineurin/NFAT signalling pathway in heart failure mice. J Physiol. 2009;  587 (Pt 15): 3899-910.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice</article-title>
          <source>J Physiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>3899</fpage>
          <lpage>910</lpage>
          <issue>15</issue>
          <volume>587</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Paixao</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Rolim</surname>
              <given-names>NP</given-names>
            </name>
            <name>
              <surname>Medeiros</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35.  Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, et al. Activation or  inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological  hypertrophy. J Cell Physiol. 2008; 214 (2): 316-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy</article-title>
          <source>J Cell Physiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>316</fpage>
          <lpage>21</lpage>
          <issue>2</issue>
          <volume>214</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kemi</surname>
              <given-names>OJ</given-names>
            </name>
            <name>
              <surname>Ceci</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wisloff</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Grimaldi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gallo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>GL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36.  Meris A, Amigoni M, Uno H, Thune JJ, Verma A, Kober L, et al. Left atrial remodelling  in patients with myocardial infarction complicated by heart failure, left ventricular  dysfunction, or both: the VALIANT Echo study. Eur Heart J. 2009; 30 (1): 56-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>56</fpage>
          <lpage>65</lpage>
          <issue>1</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Meris</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Amigoni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uno</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Thune</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Verma</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kober</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37.  Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical  outcomes in heart failure patients with left ventricular systolic dysfunction.  J Card Fail. 2002; 8 (6 Suppl): S465-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>S465</fpage>
          <lpage>71</lpage>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Udelson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Konstam</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38.  Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE, et al. Left  ventricular reverse remodeling but not clinical improvement predicts long-term  survival after cardiac resynchronization therapy. Circulation. 2005; 112 (11):  1580-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bleeker</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Fung</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Schalij</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wall EE</surname>
              <given-names>van der</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39.  Garciarena CD, Pinilla OA, Nolly MB, Laguens RP, Escudero EM, Cingolani HE, et  al. Endurance training in the spontaneously hypertensive rat: conversion of pathological  into physiological cardiac hypertrophy. Hypertension. 2009; 53 (4): 708-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endurance training in the spontaneously hypertensive rat: conversion of pathological into physiological cardiac hypertrophy</article-title>
          <source>Hypertension</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>708</fpage>
          <lpage>14</lpage>
          <issue>4</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garciarena</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Pinilla</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Nolly</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Laguens</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Escudero</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Cingolani</surname>
              <given-names>HE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40.  Xu X, Wan W, Powers AS, Li J, Ji LL, Lao S, et al. Effects of exercise training  on cardiac function and myocardial remodeling in post myocardial infarction rats.  J Mol Cell Cardiol. 2008; 44 (1): 114-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of exercise training on cardiac function and myocardial remodeling in post myocardial infarction rats</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>114</fpage>
          <lpage>22</lpage>
          <issue>1</issue>
          <volume>44</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ji</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Lao</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Association of physical training with beta-blockers in heart failure in mice</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Currently there are several types of interventions for the treatment of heart failure (HF). Among these are beta-blocker therapy (BB) and physical training (PT). However, the effects of the combination of these therapies are poorly studied. OBJECTIVE: To investigate the effects of BB treatment with metoprolol (M) and carvedilol (C) associated with PT in mice with HF. METHODS: We used a genetic model of sympathetic hyperactivity-induced heart failure in mice. Initially, we divided the HF animals into three groups: sedentary (S); trained (T); treated with M (138 mg/kg) (M); or C (65 mg/kg) (C). In the second part, we divided the groups into three subgroups: sedentary (S); trained and treated with M (TM); and trained and treated with C (CT). The PT consisted of aerobic training on a treadmill for 8 weeks. Exercise tolerance was assessed by maximal graded test, and fractional shortening (FS) was assessed by echocardiography. Cardiomyocyte diameter and collagen volume fraction were evaluated by histological analysis. Data were compared by one way ANOVA and post hoc Duncan test. The significance level was set at p &lt; 0.05. RESULTS: As to FS and cardiac remodeling, we found that, in isolation, T, M, and C showed an improvement of the variables analyzed. As to therapy combination, after the intervention period, we observed an increase in exercise tolerance in MT and CT (43.0% and 33.0% respectively). There was also a reduction in cardiomyocyte diameter (10.0% and 9.0% respectively) and in collagen volume fraction (52.0% and 63.0%) after the intervention. However, only CT significantly improved FS. CONCLUSION: The association of PT with M or C therapies provided benefits on cardiac function and remodeling in HF mice.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>training</kwd>
        <kwd>exercise</kwd>
        <kwd>sympathetic nervous system</kwd>
        <kwd>b-blockers</kwd>
        <kwd>mice</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLES</bold>
      </p>
      <p><undefined id="topo-body2"/>Association of physical training with beta-blockers in heart failure in mice</p>
      <p>
        <bold>Andr&#233;a Somolanji Vanzelli<sup>I,II</sup>; Alessandra Medeiros<sup>III</sup>; Raquel de Assis Sirvente<sup>II</sup>; Vera Maria Cury Salemi<sup>II</sup>; Charles Mady<sup>II</sup>; Patricia Chakur Brum<sup>I</sup></bold>
      </p>
      <p><sup>I</sup>Escola de Educa&#231;&#227;o F&#237;sica da Universidade de S&#227;o Paulo</p>
      <p><sup>II</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (FMUSP)</p>
      <p><sup>III</sup>Universidade Federal de S&#227;o Paulo (UNIFESP)<sup>III</sup>, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Currently there are several types of interventions for the treatment of heart failure (HF). Among these are beta-blocker therapy (BB) and physical training (PT). However, the effects of the combination of these therapies are poorly studied.</p>
      <p><bold>OBJECTIVE:</bold> To investigate the effects of BB treatment with metoprolol (M) and carvedilol (C) associated with PT in mice with HF.</p>
      <p><bold>METHODS:</bold> We used a genetic model of sympathetic hyperactivity-induced heart failure in mice. Initially, we divided the HF animals into three groups: sedentary (S); trained (T); treated with M (138 mg/kg) (M); or C (65 mg/kg) (C). In the second part, we divided the groups into three subgroups: sedentary (S); trained and treated with M (TM); and trained and treated with C (CT). The PT consisted of aerobic training on a treadmill for 8 weeks. Exercise tolerance was assessed by maximal graded test, and fractional shortening (FS) was assessed by echocardiography. Cardiomyocyte diameter and collagen volume fraction were evaluated by histological analysis. Data were compared by one way ANOVA and <italic>post hoc </italic>Duncan test. The significance level was set at p <underline>&lt;</underline> 0.05.</p>
      <p><bold>RESULTS:</bold> As to FS and cardiac remodeling, we found that, in isolation, T, M, and C showed an improvement of the variables analyzed. As to therapy combination, after the intervention period, we observed an increase in exercise tolerance in MT and CT (43.0% and 33.0% respectively). There was also a reduction in cardiomyocyte diameter (10.0% and 9.0% respectively) and in collagen volume fraction (52.0% and 63.0%) after the intervention. However, only CT significantly improved FS.</p>
      <p><bold>CONCLUSION:</bold> The association of PT with M or C therapies provided benefits on cardiac function and remodeling in HF mice. </p>
      <p><bold>Key words:</bold> Heart failure; training; exercise; sympathetic nervous system; angiotensin-converting enzyme inhibitors; rats.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure is the final common pathway for many cardiovascular diseases. It is a syndrome characterized by signs and symptoms related to inadequate tissue perfusion<sup>1</sup> and cathecolamine excess<sup>2</sup>. According to the hemodynamic view, heart failure syndrome is associated with low cardiac output, with consequent low renal flow, resulting in sodium and water retention and the appearance of peripheral and pulmonary edema<sup>3</sup>. Another common feature of heart failure is cardiac remodeling associated with loss of cardiomyocytes and increased collagen fraction<sup>4,5</sup>.</p>
      <p>In the last two decades, there was a remarkable progress in the treatment of HF. The introduction of beta blockers and renin-angiotensin-aldosterone inhibitors made a considerable difference in the clinical evolution of patients, offering a more promising prospect for greater survival. Relevant clinical trials showed an unprecedented mortality reduction in the treatment of HF<sup>6-10</sup>.</p>
      <p>There are increased possibilities of therapeutic and clinical optimization when non-pharmacological measures, such as diet and regular physical activity, are associated with conventional pharmacological treatment. Actually, physical training has been increasingly adopted, and its benefits include improved quality of life and tolerance to physical exertion, besides a reduction in the hyperactivity of the neurohumoral system, which is directly related to improved survival rates<sup>11</sup> and autonomic balance<sup>12-14</sup>.</p>
      <p>In previous laboratory studies we demonstrated that a therapy with the beta-blocker carvedilol significantly reduced sympathetic nerve activity in patients with HF<sup>15</sup>. More recently, we demonstrated that a non-pharmacological therapy based on exercise training resulted in additional reduction in sympathetic activity in HF patients who were already under therapy with the beta-blocker carvedilol<sup>16</sup>. These results suggest that the association of physical training with beta-blocker therapy can optimize the reduction in the hyperactivity of the neurohumoral system.</p>
      <p>In this study, we used a genetic model of sympathetic hyperactivity-induced HF in mice to study the effect of the combination of the beta blockers metoprolol or carvedilol with aerobic exercise training on cardiac function and structure.</p>
      <p>
        <bold>Material and methods</bold>
      </p>
      <p>
        <bold>Sample</bold>
      </p>
      <p>We used male mice of the C57/BL6 strain with gene inactivation of the &#945;<sub>2A</sub>/&#945;<sub>2C</sub> adrenergic receptor (&#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice), aged between 5-7 months, from the Laboratory Animal Facility of the School of Physical Education and Sports of the University of S&#227;o Paulo (n = 35). These mice develop clinical signs of HF such as pulmonary edema associated with severe ventricular dysfunction at 7 months of age, when the mortality rate is 50.0%<sup>12,17</sup>. The gene inactivation of the &#945;<sub>2A</sub> and &#945;<sub>2C</sub> adrenergic receptors leads to an increase in the release of circulating noradrenaline<sup>18,19</sup>. Therefore, the HF observed in this model results from sympathetic nervous system hyperactivity.</p>
      <p>This study was approved by the Ethics Committee of the Medical School of the University of S&#227;o Paulo (897/06).</p>
      <p>As a first step in our study, in order to evaluate the effect of isolated therapies on the variables analised, the animals were randomly divided into four groups: &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO sedentary mice (S); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO trained mice (T); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice treated with metoprolol (M); and &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice treated with carvedilol (C). After observing the isolated effect of the treatments, the effects of combined therapies were evaluated and, for that end, the animals were randomly divided into the following subgroups: &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO sedentary mice (S); &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice trained and treated with metoprolol (MT); and &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice trained and treated with carvedilol (CT).</p>
      <p>Control mice without HF (WT) are shown in the figures of the study with a dashed line to indicate the expected value in a control group without heart failure.</p>
      <p>The treatments were carried out by gavage, and the doses used were previously tested in order to adjust them and to obtain equipotent doses for reducing the heart rate of animals, which corresponded to 135 mg/kg and 68 mg/kg for metoprolol and carvedilol, respectively<sup>20,21</sup>.</p>
      <p>Body weight was monitored weekly in a semi-analytical scale (Gehaka, BG 400 - S&#227;o Paulo, Brazil).</p>
      <p>
        <bold>Maximum capacity of physical exercise</bold>
      </p>
      <p>Intolerance to exertion was estimated in the groups studied by quantifying the maximum capacity to perform physical exercise (total test time in seconds) using a phased progressive exercise test to exhaustion, which was evidenced when the animal could not continue running on the treadmill (manufactured by the Federal University of S&#227;o Carlos, S&#227;o Carlos, Brazil) with an initial velocity of 3 m/min, and an increase of 3 m/min every 3 min<sup>12</sup>.</p>
      <p>
        <bold>Aerobic exercise training protocol</bold>
      </p>
      <p>The groups of trained animals underwent a program of aerobic exercise training on treadmill for 8 weeks (from 5 to 7 months of age). The exercise sessions were conducted 5 times per week, lasting 60 minutes per session, with an intensity of 60.0% of the maximum speed recorded in the progressive test to exhaustion, which, as noted in a previous study, corresponds to the maximum lactate steady state<sup>22</sup> ie, corresponds to the maximum exercise intensity in which there is a balance between production and removal of blood lactate during prolonged exercise.</p>
      <p>
        <bold>Indirect measurement of blood pressure and heart rate</bold>
      </p>
      <p>We performed an indirect measurement of blood pressure using the tail plethysmographic method over the 8 weeks of intervention (Kent Scientific, CODA - Torrington, CT, USA). By using the pressure pulses recorded, we calculated the heart rate of the mice, as had already been done in previous studies<sup>13,20,21,23</sup>.</p>
      <p>
        <bold>Echocardiographic assessment</bold>
      </p>
      <p>The transthoracic echocardiography was performed before and after the intervention period in all groups. The echocardiographic examination was performed with the animals anesthetized with the inhalation of the anesthetic halothane 1.0%, mixed with an O<sub>2</sub> flow of 1 l/min. We used an echocardiograph (Acuson Corporation, Sequoia 512 - Mountain View, CA, USA) with a 15 MHz transducer. Images were taken at a frequency of 14 MHz. From the visualization of the left ventricle (cross section) at the level of the papillary muscles, M-mode was performed, and the diastolic diameter (LVDD) and the systolic diameter (LVSD) of the left ventricle were obtained and used to calculate fractional shortening (FS). The formula used was: FS = (LVDD - LVSD)/LVDD. The echocardiographer (R. S.) was blinded to the genotype and the type of treatment of the animals.</p>
      <p>
        <bold>Cardiac morphological and morphometric analyses</bold>
      </p>
      <p>After 48 hours of formalin fixation (4.0%), the left ventricle was subjected to the usual histological processing, with 2 micron slices and hematoxylin-eosin or picrosirius <italic>red</italic> staining for the quantification of the cardiomyocyte cross-sectional diameter and the cardiac collagen fraction, respectively. These measurements were performed in a computerized system <italic>(Leica Imaging Systems</italic> Ltd., Quantimet 500 - Cambridge, UK, England), with a magnification of 400x and 200x, respectively. The cardiomyocyte diameter was determined as the mean of 10 measured values for each animal.</p>
      <p>The collagen volume fraction was calculated as the percent ratio between the myocardial tissue area positively stained for collagen fibers (the absolute amount of collagen) and the total area of myocardial tissue in each ventricular region examined (absolute amount of collagen and myocytes), field by field. About 15-20 fields were examined for each animal<sup>13,20,21,23,24</sup>.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>All variables showed normal distribution, when analyzed using the Shapiro-Wilk normality test, and therefore, the parametric statistical analysis was used. Data were expressed as mean &#177; standard error of mean.</p>
      <p>The variables were compared among groups by one-way analysis of variance (ANOVA) (cardiomyocyte cross-sectional diameter and collagen fraction volume), or one way repeated measures (exercise tolerance, fractional shortening, and heart rate). For mortality, <italic>log rank </italic>analysis was used. For cases in which some significance was shown, <italic>post hoc</italic> Duncan's test was used. For all analyses, we adopted the significance level of p &lt; 0.05. The software used for statistical analysis was <italic>Statistica</italic> version 6.0.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>
        <bold>Isolated effect of treatments (physical training, metoprolol, and carvedilol on exercise tolerance, cardiac structure, and contractile function)</bold>
      </p>
      <p>In <xref ref-type="fig" rid="abc_nahead2210_aop09310_ing_fig01-body2">Figure 1</xref>, Panel A, which highlights the isolated effects of the treatments on exercise tolerance, we observed that exercise training alone leads to a significant improvement in exercise tolerance, which is not observed in groups treated with the beta blockers metoprolol and carvedilol. As to ventricular function, we observed that all treatments (PT, M, or C) similarly improved the fractional shortening (<xref ref-type="fig" rid="abc_nahead2210_aop09310_ing_fig01-body2">Figure 1B</xref>).</p>
      <p><fig id="abc_nahead2210_aop09310_ing_fig01-body2"/>&#13;
&#160;&#13;
</p>
      <p>
        <fig id="aop09310_ing_fig01abm-body2">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf01-en.jpg"/></fig>
      </p>
      <p>&#13;
  <fig id="abc_nahead2210_aop09310_ing_fig01xfig1cd-body2"/><fig id="aop09310_ing_fig01cdm-body2"><graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf02-en.jpg"/></fig></p>
      <p>Regarding the effects on cardiac structure, physical training alone did not result in a significant reduction of the cardiomyocyte cross-sectional diameter; however, it had effects similar to the pharmacological therapies in reducing the cardiac collagen fraction (<xref ref-type="fig" rid="abc_nahead2210_aop09310_ing_fig01-body2">Figures 1C</xref> and <xref ref-type="fig" rid="abc_nahead2210_aop09310_ing_fig01-body2">1D</xref>).</p>
      <p>
        <bold>Effects of the combination of physical training with treatment with beta blockers</bold>
      </p>
      <p>During the experimental period, the body weight of the animals was measured weekly. We observed that &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO animals initially had lower body mass than those of the WT control group (22.2 &#177; 1.3 g <italic>vs</italic> 28.3 &#177; 2.2 g, p <underline>&lt;</underline> 0.05). Neither group showed a change in mass during the intervention period.</p>
      <p>Additionally, we evaluated the mortality curve during the intervention period and found no significant difference among groups (40.0% <italic>vs</italic> 20.0% and 18.0% for groups S, MT, and CT, respectively, p <underline>&lt;</underline> 0.05).</p>
      <p>
        <bold>Maximum exercise tolerance</bold>
      </p>
      <p>In <xref ref-type="fig" rid="aop09310_ing_fig02m-body2">Figure 2</xref>, we observe that the association of physical training with beta-blocker therapy significantly improved the exercise tolerance when compared to the group treated with saline (S).</p>
      <p content-type="asset">
        <fig id="aop09310_ing_fig02m-body2">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf03-en.jpg"/></fig>
      </p>
      <p>It should be emphasized that exercise tolerance in &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO animals reached the values observed in control mice without HF (<xref ref-type="fig" rid="aop09310_ing_fig02m-body2">Figure 2</xref>, dashed line); also, the groups that were trained and treated with the beta blockers metoprolol and carvedilol were equally effective in improving exercise tolerance (43.0% and 33.0% increase, respectively).</p>
      <p>
        <bold>Heart rate and blood pressure</bold>
      </p>
      <p>As shown in <xref ref-type="fig" rid="aop09310_ing_fig03m-body2">Figure 3</xref>, &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice have resting tachycardia compared to control WT mice (711 &#177; 3 <italic>vs</italic> 617 &#177; 24 bpm, respectively, p <underline>&lt;</underline> 0.05). The association of physical training with therapy with beta blockers similarly reduced the heart rate of &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice, from the 4<sup>th</sup> week of intervention, to values similar to the heart rate observed in control mice without HF (WT, dashed line). There was no difference in blood pressure between groups over the eight weeks of intervention (114 &#177; 7.3 mmHg at week 8 of study).</p>
      <p content-type="asset">
        <fig id="aop09310_ing_fig03m-body2">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf04-en.jpg"/></fig>
      </p>
      <p>
        <bold>Fractional shortening</bold>
      </p>
      <p>By 8 weeks after the intervention, only the &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice group trained and treated with carvedilol (CT) significantly improved in values of fractional shortening (<xref ref-type="fig" rid="aop09310_ing_fig04m-body2">Figure 4</xref>) compared to the &#945;<sub>2A</sub>/&#945;<sub>2C</sub>ARKO mice group treated with saline (20 &#177; 0.8 <italic>vs</italic> 15 &#177; 0.4%, respectively, p <underline>&lt;</underline> 0.05), reaching values similar to those of the control group without HF (WT). Interestingly, the association of metoprolol with PT did not improve fractional shortening. This result was unexpected because both metoprolol alone and PT alone were able to increase fractional shortening (<xref ref-type="fig" rid="abc_nahead2210_aop09310_ing_fig01-body2">Figure 1B</xref>).</p>
      <p content-type="asset">
        <fig id="aop09310_ing_fig04m-body2">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf05-en.jpg"/></fig>
      </p>
      <p>
        <bold>Cardiomyocyte diameter and collagen volume fraction</bold>
      </p>
      <p>The morphometric assessment showed that both cardiac beta-blockers associated with exercise training were equally effective in significantly reducing cardiomyocyte cross-sectional diameter (10.0% and 9.0% for the trained groups treated with metoprolol and carvedilol, respectively) and cardiac collagen fraction (52.0% and 63.0% for the trained groups treated with metoprolol and carvedilol, respectively), suggesting a possible effect of reverse cardiac remodeling associated with the combined effects of both beta-blockers to physical training (<xref ref-type="fig" rid="aop09310_ing_fig05m-body2">Figure 5</xref>).</p>
      <p content-type="asset">
        <fig id="aop09310_ing_fig05m-body2">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf06-en.jpg"/></fig>
      </p>
      <p>In mice with sympathetic hyperactivity-induced cardiomyopathy as well as in clinical HF, the manifestation of clinical signs, such as intolerance to exertion, pulmonary edema, decreased cardiac function, and cardiac remodeling, is very common. It is important to emphasize that, even though a cause-effect on sympathetic hyperactivity has not been established in clinical heart failure, the autonomic imbalance plays an important role in the patient's prognosis, which makes the mice model used in this study even more interesting, because it allows for studies evaluating the direct effect of sympathetic hyperactivity in HF.</p>
      <p>Following this addendum, the main results of this study in mice with sympathetic hyperactivity-induced HF were:</p>
      <p>1) Both metoprolol and carvedilol, when combined with physical training, similarly improved tolerance to exertion and reduced resting tachycardia in an equipotent manner;</p>
      <p>2) Both physical and pharmacologic therapies, individually, and the association of carvedilol with physical training significantly improved fractional shortening;</p>
      <p>3) Both metoprolol and carvedilol associated with physical training similarly reduced collagen volume fraction and cardiomyocyte cross-sectional diameter.</p>
      <p>We demonstrated previously that exercise training improved fractional shortening in heart failure by improving the calcium transient and the expression profile of proteins that regulate intracellular Ca<sup>2+</sup> flow<sup>13,23</sup>. The association of metoprolol with physical training seems to be less effective, probably because metoprolol has a cardiac effect similar to that of PT, i.e. it is more associated with the calcium transient and not with reducing oxidative stress.<sup>20</sup></p>
      <p>Although carvedilol and metoprolol in combination with exercise training produced different effects on ventricular contractility, both were equally effective in improving tolerance to exertion when combined with exercise training.</p>
      <p>The increased tolerance to physical exertion is not associated only with an improved cardiac function, but with the combination of better cardiac performance with beneficial adaptations in non-cardiac target organs. This may include the vasodilator response in the vascular endothelium, the cardiac output distribution, the ventilatory response<sup>25</sup>, and changes in skeletal muscles.</p>
      <p>Skeletal muscle structure analyses, conducted in the same genetic model used in this study, with &#945;<sub>2A</sub>/&#945;<sub>2C-</sub>ARKO mice of 7 months of age, using the technique of staining for myosin ATPase, showed a decreased cross-sectional area of muscle fibers, a phenotypic change of fiber type I to type II fibers, and capillary rarefaction. Besides, the changes described appear to be accompanied by a change in the metabolic profile, with a reduced activity of oxidative enzymes<sup>26</sup>. This may be associated with the progressive reduction in exercise tolerance observed in this study.</p>
      <p>With regard to the effects of beta blockers in tolerance to exertion, several studies in the literature have examined their use in patients with various heart diseases<sup>27,28</sup>. Clinical trials that have lasted for more than a month have observed significant improvements in ventricular function, but very subtle improvement in exercise tolerance<sup>27,28</sup>. Therefore, physical training seems to play a key role in improving tolerance to exertion in mice with heart failure , corroborating the results of other studies that show the same effect<sup>29,30</sup>.</p>
      <p>Similarly to what was observed for tolerance to exertion, heart rate reduction had the same outcome pattern in the groups treated with metoprolol and carvedilol associated with physical training. Both had equipotent effects on HR, reducing it to values similar to those observed in WT mice (dashed line), and thus showing the effectiveness of the treatment with both beta-blockers in reducing tachycardia in this model of cardiomyopathy, which is related to an increased activity of the sympathetic nervous system. Therefore, these bradycardic effects in mice, may suggest an improvement in the autonomic balance, which, in turn, is associated with an improved prognosis and survival in heart failure<sup>16,31</sup>. Moreover, high values of heart rate are also independent predictors of mortality in the general population<sup>32,33</sup>.</p>
      <p>Besides changes in ventricular function, our results also suggest the presence of cardiac remodeling in mice with heart failure (<xref ref-type="fig" rid="aop09310_ing_fig04m-body2">Figure 4</xref>). Both beta-blockers in combination with exercise training had beneficial effects on cardiac structure and prevented cardiomyocyte hypertrophy and cardiac collagen increase.</p>
      <p>Actually, physical training has an effect on the reverse remodeling associated with a reduction in the calcineurin signaling pathway, which is related to pathological hypertrophy<sup>34</sup>, or Akt activation, which in turn is related to physiological hypertrophy<sup>35</sup>. Therefore, the association of PT to beta-blockers is an approach to be adopted, because remodeling is highly related to death in patients with HF<sup>36-38</sup>.</p>
      <p>Other effects of physical training on minimizing the process of myocardial failure have recently been shown and may be associated with a reduction in proteins associated with fibrosis and cardiac remodeling, among other factors<sup>39,40</sup>.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The association of physical training to therapy with metoprolol or carvedilol similarly improved tolerance to exertion and also improved the cardiac structure in mice with HF induced by sympathetic hyperactivity. However, only carvedilol, when associated with PT, improved contractility.</p>
      <p>
        <bold>Acknowledgements</bold>
      </p>
      <p>The authors would like to express their appreciation to the School of Medicine and the School of Physical Education and Sports of the University of S&#227;o Paulo. Also to FAPESP for funding the study (06/56123-0, 05/59740-7). PCB has been awarded an ID level researcher scholarship by CNPq (301519/2008-0).</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was funded by FAPESP.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of doctoral submitted by Andr&#233;a Somolanji Vanzelli, from <italic>Faculdade de Medicina da Universidade de S&#227;o Paulo</italic>.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Asociaci&#243;n de betabloqueantes y entrenamiento f&#237;sico en la insuficiencia card&#237;aca de ratones</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El tratamiento de la insuficiencia cardiaca (IC) cuenta actualmente con diversos tipos de intervenciones. De entre ellas podemos destacar la terapia con betabloqueantes (BB) y el entrenamiento f&#237;sico (EF). Con todo, los efectos de la asociaci&#243;n de estas terapias son poco estudiados. OBJETIVO: Verificar los efectos del tratamiento con BB, metoprolol (M) y carvedilol (C) asociados al EF en la IC en ratones. M&#201;TODOS: Utilizamos modelo gen&#233;tico de IC inducida en ratones por hiperactividad simp&#225;tica. Inicialmente, dividimos los animales con IC en: sedentarios (S); entrenados (E); tratados con M (138 mg/kg) (M) o C (65 mg/kg) (C). En la segunda parte, dividimos los grupos en S; entrenado y tratado con M (ME) y entrenado y tratado con C (CE). El EF consisti&#243; en entrenamiento aer&#243;bico en estera por 8 semanas. La tolerancia al esfuerzo se evalu&#243; por prueba progresivo m&#225;xima y la fracci&#243;n de acortamiento se evalu&#243; (FE) por ecocardiograf&#237;a. El di&#225;metro de los cardiomiocitos y la fracci&#243;n de col&#225;geno fueron evaluados por medio de an&#225;lisis histol&#243;gico. Los dados fueron comparados por ANOVA de un camino con post hoc de Duncan. El nivel de significancia se consider&#243; como p &lt; 0,05. RESULTADOS: Destacando FE y remodelaci&#243;n card&#237;aca, verificamos que, aisladamente, E, M y C presentaron mejora de las variables. En la asociaci&#243;n, tras el per&#237;odo de intervenci&#243;n, observamos aumento de la tolerancia al esfuerzo en ME y CE (el 43% y el 33%, respectivamente). Hubo tambi&#233;n reducci&#243;n del di&#225;metro de los cardiomiocitos (el 10% y el 9%, respectivamente) y de la fracci&#243;n de col&#225;geno (el 52% y el 63%), tras la intervenci&#243;n. Sin embargo, solamente CE mejor&#243; significantemente la FE. CONCLUSI&#211;N: La asociaci&#243;n del EF a las terapias con M o C proporcion&#243; beneficios sobre la funci&#243;n y remodelaci&#243;n card&#237;aca en ratones con IC.&lt;/</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia cardiaca</kwd>
        <kwd>entrenamiento</kwd>
        <kwd>ejercicio</kwd>
        <kwd>sistema nervioso simp&#225;tico</kwd>
        <kwd>inhibidores de la enzima convertidora de la angiotensina</kwd>
        <kwd>ratones</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Asociaci&#243;n de betabloqueantes y entrenamiento f&#237;sico en la insuficiencia card&#237;aca de ratones</bold>
          </label>
          <p>
            <bold>Andr&#233;a Somolanji Vanzelli<sup>I, II</sup>; Alessandra Medeiros<sup>III</sup>; Raquel de Assis Sirvente<sup>II</sup>; Vera Maria Cury Salemi<sup>II</sup>; Charles Mady<sup>II</sup>; Patricia Chakur Brum<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Escola de Educa&#231;&#227;o F&#237;sica da Universidade de S&#227;o Paulo, S&#227;o Paulo, SP - Brasil</p>
      <p><sup>II</sup>Faculdade de Medicina da Universidade de S&#227;o Paulo (FMUSP), S&#227;o Paulo, SP - Brasil</p>
      <p><sup>III</sup>Universidade Federal de S&#227;o Paulo (UNIFESP), S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> El tratamiento de la insuficiencia cardiaca (IC) cuenta actualmente con diversos tipos de intervenciones. De entre ellas podemos destacar la terapia con betabloqueantes (BB) y el entrenamiento f&#237;sico (EF). Con todo, los efectos de la asociaci&#243;n de estas terapias son poco estudiados.</p>
      <p><bold>OBJETIVO:</bold> Verificar los efectos del tratamiento con BB, metoprolol (M) y carvedilol (C) asociados al EF en la IC en ratones.</p>
      <p><bold>M&#201;TODOS:</bold> Utilizamos modelo gen&#233;tico de IC inducida en ratones por hiperactividad simp&#225;tica. Inicialmente, dividimos los animales con IC en: sedentarios (S); entrenados (E); tratados con M (138 mg/kg) (M) o C (65 mg/kg) (C). En la segunda parte, dividimos los grupos en S; entrenado y tratado con M (ME) y entrenado y tratado con C (CE). El EF consisti&#243; en entrenamiento aer&#243;bico en estera por 8 semanas. La tolerancia al esfuerzo se evalu&#243; por prueba progresivo m&#225;xima y la fracci&#243;n de acortamiento se evalu&#243; (FE) por ecocardiograf&#237;a. El di&#225;metro de los cardiomiocitos y la fracci&#243;n de col&#225;geno fueron evaluados por medio de an&#225;lisis histol&#243;gico. Los dados fueron comparados por ANOVA de un camino con post hoc de Duncan. El nivel de significancia se consider&#243; como p <bold><underline>&lt;</underline></bold> 0,05.</p>
      <p><bold>RESULTADOS:</bold> Destacando FE y remodelaci&#243;n card&#237;aca, verificamos que, aisladamente, E, M y C presentaron mejora de las variables. En la asociaci&#243;n, tras el per&#237;odo de intervenci&#243;n, observamos aumento de la tolerancia al esfuerzo en ME y CE (el 43% y el 33%, respectivamente). Hubo tambi&#233;n reducci&#243;n del di&#225;metro de los cardiomiocitos (el 10% y el 9%, respectivamente) y de la fracci&#243;n de col&#225;geno (el 52% y el 63%), tras la intervenci&#243;n. Sin embargo, solamente CE mejor&#243; significantemente la FE.</p>
      <p><bold>CONCLUSI&#211;N:</bold> La asociaci&#243;n del EF a las terapias con M o C proporcion&#243; beneficios sobre la funci&#243;n y remodelaci&#243;n card&#237;aca en ratones con IC.</p>
      <p><bold>Palabras clave: </bold> Insuficiencia cardiaca, entrenamiento, ejercicio, sistema nervioso simp&#225;tico, inhibidores de la enzima convertidora de la angiotensina, ratones.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca es la v&#237;a final com&#250;n para diversas enfermedades cardiovasculares, constituy&#233;ndose en un s&#237;ndrome caracterizado por se&#241;ales y s&#237;ntomas relacionados a la perfusi&#243;n tisular inadecuada<sup>1</sup> y al exceso de catecolaminas<sup>2</sup>. De acuerdo con la visi&#243;n hemodin&#225;mica, el s&#237;ndrome de la insuficiencia cardiaca est&#225; asociada a un bajo gasto cardiaco, con consecuente bajo flujo renal, conllevando la retenci&#243;n de sodio y agua y la aparici&#243;n de edemas perif&#233;rico y pulmonar<sup>3</sup>. Otra caracter&#237;stica com&#250;n de la insuficiencia cardiaca es la remodelaci&#243;n card&#237;aca asociada a la p&#233;rdida de cardiomiocitos y al aumento de la fracci&#243;n de col&#225;geno<sup>4,5</sup>.</p>
      <p>En las dos &#250;ltimas d&#233;cadas, hubo notorio progreso en el tratamiento de la IC. La introducci&#243;n de los agentes betabloqueantes y de los inhibidores del sistema renina-angiotensina-aldosterona provoc&#243; un n&#237;tido cambio en el comportamiento cl&#237;nico de los pacientes, as&#237; como trajo la perspectiva de &#237;ndices de sobrevida m&#225;s promisores. Ensayos cl&#237;nicos mostraron reducciones relevantes de la mortalidad como nunca presentado anteriormente en el tratamiento de la IC<sup>6-10</sup>.</p>
      <p>Las posibilidades de optimizaci&#243;n terap&#233;utica y cl&#237;nica se ampl&#237;an cuando mediciones no farmacol&#243;gicas, tales como dieta y actividad f&#237;sica regular, son asociadas al tratamiento farmacol&#243;gico convencional. De hecho, el entrenamiento f&#237;sico aer&#243;bico se viene adoptando cada vez m&#225;s y sus beneficios incluyen mejora en la calidad de vida del paciente y tolerancia a esfuerzos f&#237;sicos, adem&#225;s de la reducci&#243;n en la hiperactividad de sistemas neurohumorales que est&#225; directamente relacionada a la mejora en la sobrevida del paciente<sup>11</sup> y en el balance auton&#243;mico<sup>12-14</sup>.</p>
      <p>En estudios anteriores de nuestro laboratorio, demostramos que la terapia con el betabloqueante carvedilol redujo significantemente la actividad nerviosa simp&#225;tica en pacientes con IC<sup>15</sup>, y, m&#225;s recientemente, revelamos que la terapia no farmacol&#243;gica con el entrenamiento f&#237;sico aerobio provoc&#243; reducci&#243;n adicional en la actividad simp&#225;tica de pacientes con IC que ya estaban bajo terapia con el betabloqueante carvedilol<sup>16</sup>. Estos resultados sugieren que la asociaci&#243;n del entrenamiento f&#237;sico aer&#243;bico al betabloqueante es capaz de optimizar la reducci&#243;n en la hiperactividad de sistemas neurohumorales.</p>
      <p>En el presente estudio, utilizamos un modelo gen&#233;tico de IC inducida por hiperactividad simp&#225;tica en ratones para estudiar el efecto de la asociaci&#243;n de los betabloqueantes metoprolol o carvedilol al entrenamiento f&#237;sico aer&#243;bico sobre la funci&#243;n y la estructura card&#237;acas.</p>
      <p>
        <bold>Material y m&#233;todos</bold>
      </p>
      <p>
        <bold>Muestra</bold>
      </p>
      <p>Se utilizaron ratones machos de linaje C57/BL6 con inactivaci&#243;n g&#233;nica de los receptores a<sub>2A</sub>/a<sub>2C</sub> adrenergicos (a<sub>2A</sub>/a<sub>2C</sub>ARKO), en el grupo de edad comprendida entre los 5-7 meses de vida, provenientes del Bioterio de la Escuela de Educaci&#243;n F&#237;sica y Deporte de la USP (n = 35). Estos ratones desarrollan se&#241;ales cl&#237;nicos de IC como edema pulmonar asociado a la disfunci&#243;n ventricular severa a los 7 meses de edad, cuando a tasa de mortalidad es del 50%<sup>12,17</sup>. La inactivaci&#243;n g&#233;nica de los receptores a<sub>2A</sub> y a<sub>2C</sub> adrenergicos provoca la elevaci&#243;n en la liberaci&#243;n de noradrenalina circulante<sup>18,19</sup>, siendo, por tanto, la IC observada en este modelo debido a la hiperactividad del sistema nervioso simp&#225;tico.</p>
      <p>El presente estudio se aprob&#243; en el Comit&#233; de &#201;tica de la Facultad de Medicina de la USP (897/06).</p>
      <p>En una primera etapa de nuestro trabajo, con el intuito de evaluarse el efecto de las terapias aisladas sobre las variables analizadas, dividimos los animales aleatoriamente en a<sub>2A/</sub>a<sub>2C</sub>ARKO sedentario (S); a<sub>2A/</sub>a<sub>2C</sub>ARKO entrenado (E); a<sub>2A/</sub>a<sub>2C</sub>ARKO tratado con metoprolol (M) a<sub>2A/</sub>a<sub>2C</sub>ARKO tratado con carvedilol (C). Despu&#233;s de conocer el efecto aislado de los tratamientos, evaluamos el efecto de las terapias asociadas y, para esto, los animales se subdividieron aleatoriamente en los siguientes subgrupos: a<sub>2A/</sub>a<sub>2C</sub>ARKO sedentario (S); a<sub>2A/</sub>a<sub>2C</sub>ARKO entrenado y tratado con metoprolol (ME) y grupo a<sub>2A/</sub>a<sub>2C</sub>ARKO entrenado y tratado con carvedilol (CE).</p>
      <p>Ratones control sin IC (WT) se presentan en las figuras del estudio con una l&#237;nea punteada para que se observe el valor esperado en grupo control sin insuficiencia cardiaca.</p>
      <p>Los tratamientos se llevaron a cabo realizados v&#237;a gavage y las dosis utilizadas fueron anteriormente probadas a fin de ajustarse y de obtenerse dosis equipotentes en la reducci&#243;n de la frecuencia card&#237;aca de los animales, 135 mg/kg y 68 mg/kg para metoprolol y carvedilol, respectivamente<sup>20,21</sup>.</p>
      <p>El peso corporal se sigui&#243; semanalmente en balanza semianal&#237;tica (Gehaka, BG 400 - S&#227;o Paulo, SP, Brasil)</p>
      <p>
        <bold>Capacidad m&#225;xima de realizaci&#243;n de ejercicio f&#237;sico</bold>
      </p>
      <p>La intolerancia a la realizaci&#243;n de esfuerzos se estim&#243; en los grupos estudiados por medio de la cuantificaci&#243;n de la capacidad m&#225;xima de realizaci&#243;n del ejercicio f&#237;sico (tiempo total de la prueba en segundos) a trav&#233;s de una prueba progresiva escalonada hasta el agotamiento, constatado cuando el animal no lograba mantener la corrida, en cinta rodante (confeccionada por servicio aut&#243;nomo de la Universidad Federal de S&#227;o Carlos, S&#227;o Carlos, SP, Brasil) con velocidad inicial de 3 m/min y aumento de 3 m/min a cada 3 min<sup>12</sup>.</p>
      <p>
        <bold>Protocolo de entrenamiento f&#237;sico aerobio</bold>
      </p>
      <p>Los grupos de animales entrenados se sometieron a un programa de entrenamiento f&#237;sico aer&#243;bico en cinta rodante durante 8 semanas (de los 5 a los 7 meses de edad). Las sesiones de ejercicio se llevaron a cabo 5 veces por semana, con duraci&#243;n de 60 minutos por sesi&#243;n e intensidad del 60% de la velocidad m&#225;xima verificada en la prueba progresiva hasta el agotamiento, que, conforme observamos en estudio anterior, corresponde al m&#225;ximo estado estable del lactato<sup>22</sup>, es decir, corresponde a la m&#225;xima intensidad de ejercicio f&#237;sico donde hay un equilibrio entre la producci&#243;n y la remoci&#243;n del lactato sangu&#237;neo durante el ejercicio prolongado.</p>
      <p>
        <bold>Registro indirecto de la presi&#243;n arterial y frecuencia card&#237;aca</bold>
      </p>
      <p>Se realiz&#243; la medici&#243;n indirecta de la presi&#243;n arterial mediante el m&#233;todo de pletismograf&#237;a de cola a lo largo de las 8 semanas de intervenci&#243;n (<italic>Kent Scientific</italic>, CODA - Torrington, CT, EUA) y, a trav&#233;s de los pulsos de presi&#243;n registrados, se calcul&#243; la frecuencia card&#237;aca de los ratones, conforme ya se llev&#243; a cabo en trabajos anteriores<sup>13,20,21,23</sup>.</p>
      <p>
        <bold>Evaluaci&#243;n ecocardiogr&#225;fica</bold>
      </p>
      <p>El examen ecocardiogr&#225;fico transtor&#225;cico se llev&#243; a cabo antes y tras el per&#237;odo de intervenci&#243;n en todos los grupos estudiados. El examen ecocardiogr&#225;fico se realiz&#243; con los animales anestesiados mediante el anest&#233;sico halotano 1%, con flujo 1 l/min de O<sub>2</sub> misturado al anest&#233;sico. Se utiliz&#243; el ecocardi&#243;grafo (Acuson Corporation, Sequoia 512 - Mountain View, CA, EUA), con transductor de 15 MHz. Las im&#225;genes se hicieron con una frecuencia de 14 MHz. A partir de la visualizaci&#243;n del ventr&#237;culo izquierdo (corte transversal) al nivel de los m&#250;sculos papilares, se llev&#243; a cabo el modo M y las mediciones del di&#225;metro diast&#243;lico (DDVI) y sist&#243;lico (DSVI) del ventr&#237;culo izquierdo fueron obtenidas y utilizadas para el c&#225;lculo de la fracci&#243;n de acortamiento (FS). La f&#243;rmula utilizada fue: FS = (DDVI - DSVI) / DDVI. El ecocardiografista (R. S.) estaba ciego para el genotipo y para el tipo de tratamiento de los animales.</p>
      <p>
        <bold>An&#225;lisis morfol&#243;gicos y morfom&#233;tricas card&#237;acas</bold>
      </p>
      <p>Tras 48 horas de fijaci&#243;n en formalina tamponada (4%), el ventr&#237;culo izquierdo se someti&#243; al procesamiento histol&#243;gico habitual, con cortes de 2 micra y tinci&#243;n por hematoxilina-eosina o picross&#237;rius <italic>red</italic> para la cuantificaci&#243;n del di&#225;metro transverso de los cardiomiocitos y fracci&#243;n de col&#225;geno cardiaco, respectivamente. Estas mediciones se llevaron a cabo en sistema computarizado (<italic>Leica Imaging Systems</italic> Ltda, Quantimet 500 - Cambridge, UK, Inglaterra), con aumento de 400x y 200x, respectivamente. El di&#225;metro de los cardiomiocitos se tuvo en cuenta a partir de un promedio de 10 valores medidos para cada animal.</p>
      <p>La fracci&#243;n del volumen de col&#225;geno se calcul&#243; por la raz&#243;n porcentual del &#225;rea del tejido mioc&#225;rdico sonrosado positivamente para las fibras col&#225;genas (cantidad absoluta de col&#225;geno) y el &#225;rea total del tejido mioc&#225;rdico en cada regi&#243;n ventricular examinada (cantidad absoluta de col&#225;geno y miocitos), campo a campo. Un n&#250;mero de 15 a 20 campos se examin&#243; para cada uno de los animales<sup>13,20,21,23,24</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Todas las variables estudiadas presentaron distribuci&#243;n normal, analizada por la prueba de normalidad de Shapiro-Wilk y, por tanto, se utiliz&#243; el an&#225;lisis estad&#237;stico param&#233;trico . Los datos est&#225;n representados en la forma de promedio &#177; error est&#225;ndar del promedio.</p>
      <p>Las variables estudiadas se compararon entre los grupos por el an&#225;lisis de variancia (ANOVA) de un camino (di&#225;metro transverso de los cardiomiocitos y fracci&#243;n de volumen de col&#225;geno) o un camino con mediciones repetidas (tolerancia al esfuerzo, fracci&#243;n de acortamiento y frecuencia card&#237;aca). Para la mortalidad, se utiliz&#243; el an&#225;lisis de <italic>log rank</italic>. En caso de significancia, se utiliz&#243; el <italic>post hoc</italic> de Duncan. Para todos los an&#225;lisis, se adopt&#243; como nivel de significancia p &lt; 0,05. El software para an&#225;lisis estad&#237;stica utilizado fue el <italic>Statistica</italic> Versi&#243;n 6.0.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Efecto aislado de los tratamientos (entrenamiento f&#237;sico, metoprolol y carvedilol sobre la tolerancia al esfuerzo, funci&#243;n contr&#225;ctil y estructura card&#237;aca)</p>
      <p>En la <xref ref-type="fig" rid="es_14f01-body3">Figura 1</xref>, Panel A, que resalta los efectos aislados de los tratamientos en la tolerancia al esfuerzo, se observa que el entrenamiento f&#237;sico aisladamente proporcion&#243; mejora significante de la tolerancia al esfuerzo, lo que no se observa en los grupos tratados con los betabloqueantes metoprolol y carvedilol. En cuanto a la funci&#243;n ventricular, podemos notar que todos los tratamientos (EF, M o C) mejoraron de manera similar la fracci&#243;n de acortamiento (<xref ref-type="fig" rid="es_14f01-body3">Figura 1B</xref>).</p>
      <p content-type="html"><fig id="es_14f01-body3"><graphic xlink:href="https://minio.scielo.br/documentstore/1678-4170/mbx44FBJDxLTrYqcSCDkrxq/15792abf8bf9821c74d2e775f103885b85c51abe.gif"/><graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf01-es.jpg"/></fig>&#13;
&#160;&#13;
</p>
      <p>Con relaci&#243;n a los efectos en la estructura card&#237;aca, el entrenamiento f&#237;sico aisladamente no proporcion&#243; reducci&#243;n significativa del di&#225;metro transverso de los cardiomiocitos, con todo, tuvo efectos similares a las terapias farmacol&#243;gicas en la reducci&#243;n de la fracci&#243;n de col&#225;geno cardiaco (<xref ref-type="fig" rid="es_14f01-body3">Figuras 1C</xref> y <xref ref-type="fig" rid="es_14f01-body3">1D</xref>).</p>
      <p>
        <bold>Efecto de la asociaci&#243;n del entrenamiento f&#237;sico al tratamiento con los betabloqueantes</bold>
      </p>
      <p>Durante el per&#237;odo experimental, la masa corporal de los animales se evalu&#243; semanalmente. Observamos que los animales a<sub>2A/</sub>a<sub>2C</sub>ARKO presentaban inicialmente una masa corporal menor que los animales del grupo control WT (22,2 &#177; 1,3 g <italic>vs</italic> 28,3 &#177; 2,2 g, p <underline>&lt;</underline> 0,05). Ning&#250;n de los grupos present&#243; alteraci&#243;n en la masa durante el per&#237;odo de intervenci&#243;n.</p>
      <p>Evaluamos adicionalmente la curva de mortalidad durante el per&#237;odo de intervenci&#243;n y no observamos diferencia significativa entre los grupos (40,0% <italic>vs</italic> el 20% y el 18% para los grupos S, ME y CE, respectivamente, p <underline>&lt;</underline> 0,05).</p>
      <p>
        <bold>Tolerancia al esfuerzo m&#225;ximo</bold>
      </p>
      <p>En la <xref ref-type="fig" rid="es_14f02-body3">Figura 2</xref>, se nota que la asociaci&#243;n del entrenamiento f&#237;sico a la terapia con betabloqueantes mejor&#243; significantemente la tolerancia al esfuerzo cuando comparada al grupo tratado con salina (S).</p>
      <p content-type="asset">
        <fig id="es_14f02-body3">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf02-es.jpg"/></fig>
      </p>
      <p>Cabe resaltar que la tolerancia al esfuerzo en los animales a<sub>2A/</sub>a<sub>2C</sub>ARKO alcanz&#243; los valores observados en los ratones control sin IC (<xref ref-type="fig" rid="es_14f02-body3">Figura 2</xref>, l&#237;nea punteada) y los grupos entrenados y tratados con los betabloqueantes metoprolol y carvedilol fueron igualmente eficaces en mejorar la tolerancia al esfuerzo (el 43% y el 33% de aumento, respectivamente).</p>
      <p>
        <bold>Frecuencia card&#237;aca y presi&#243;n arterial</bold>
      </p>
      <p>Como se puede observar en la <xref ref-type="fig" rid="es_14f03-body3">Figura 3</xref>, los ratones a<sub>2A/</sub>a<sub>2C</sub>ARKO presentan taquicardia de reposo cuando comparados a los ratones control WT (711 &#177; 3 <italic>vs</italic> 617 &#177; 24 lpm, respectivamente, p <underline>&lt;</underline> 0,05). La asociaci&#243;n del entrenamiento f&#237;sico a las terapias con betabloqueantes redujeron de manera similar a la frecuencia card&#237;aca de los ratones a<sub>2A</sub>/a<sub>2C</sub>ARKO, a partir de la 4&#170; semana de intervenci&#243;n, para valores semejantes a frecuencia observada en los ratones control sin IC (WT, l&#237;nea punteada). No hubo diferencia en la presi&#243;n arterial entre los grupos a lo largo de las 8 semanas de intervenci&#243;n (114 &#177; 7,3 mmHg en la 8&#170; semana del estudio).</p>
      <p content-type="asset">
        <fig id="es_14f03-body3">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf03-es.jpg"/></fig>
      </p>
      <p>
        <bold>Fracci&#243;n de acortamiento</bold>
      </p>
      <p>Tras el per&#237;odo de 8 semanas de intervenci&#243;n, solamente el grupo a<sub>2A/</sub>a<sub>2C</sub>ARKO entrenamiento y tratado con carvedilol (CE) mejor&#243; significantemente los valores de fracci&#243;n de acortamiento (<xref ref-type="fig" rid="f4-body3">Figura 4</xref>) cuando comparado al grupo a<sub>2A/</sub>a<sub>2C</sub>ARKO tratado con salina (20 &#177; 0,8 <italic>vs</italic> 15 &#177; 0,4%, respectivamente, p <underline>&lt;</underline> 0,05), alcanzando valores semejantes a los del grupo control sin IC (WT). Interesante, la asociaci&#243;n del metoprolol con EF no mejor&#243; la fracci&#243;n de acortamiento. Este resultado fue inesperado, ya que el metoprolol y el EF, aisladamente, fueron capaces de aumentar la fracci&#243;n de acortamiento (<xref ref-type="fig" rid="es_14f01-body3">Figura 1B</xref>).</p>
      <fig id="f4-body3">
        <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf04-es.jpg"/></fig>
      <p>
        <bold>Di&#225;metro dos cardiomiocitos y fracci&#243;n de col&#225;geno</bold>
      </p>
      <p>La evaluaci&#243;n morfom&#233;trica cardiaca revel&#243; que ambos betabloqueantes asociados al entrenamiento f&#237;sico fueron igualmente eficaces en reducir significantemente el di&#225;metro transverso de los cardiomiocitos (el 10% y el 9% para los grupos entrenados y tratados con metoprolol y carvedilol, respectivamente) y la fracci&#243;n de col&#225;geno card&#237;aco (el 52% y el 63% para los grupos entrenados y tratados con metoprolol y carvedilol, respectivamente), lo que sugiere un posible efecto de remodelaci&#243;n card&#237;aca reversa asociada a los efectos combinados de ambos betabloqueantes al entrenamiento f&#237;sico (<xref ref-type="fig" rid="es_14f05-body3">Figura 5</xref>).</p>
      <p content-type="asset">
        <fig id="es_14f05-body3">
          <graphic xlink:href="1678-4170-abc-95-03-0373-00098-gf05-es.jpg"/></fig>
      </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>En los ratones que constituyen tal modelo de cardiomiopat&#237;a inducida por hiperactividad simp&#225;tica, as&#237; como en la IC cl&#237;nica, es muy com&#250;n la observaci&#243;n de los signos cl&#237;nicos, como la intolerancia a los esfuerzos, el edema pulmonar, la disminuci&#243;n de la funci&#243;n card&#237;aca y la remodelaci&#243;n card&#237;aca. Es importante resaltar que, aun sin establecer una relaci&#243;n causa-efecto sobre la hiperactividad simp&#225;tica en la insuficiencia cardiaca cl&#237;nica, el desequilibrio auton&#243;mico juega un importante rol en el pron&#243;stico del paciente, lo que vuelve el modelo de ratones utilizado en el presente estudio lo m&#225;s interesante, ya que, posibilita estudiar el efecto directo de la hiperactividad simp&#225;tica en la IC.</p>
      <p>Tras hacerse esta observaci&#243;n, los principales resultados de este estudio en ratones con IC inducida por hiperactividad simp&#225;tica fueron:</p>
      <p>1) Ambos metoprolol y carvedilol, cuando asociados al entrenamiento f&#237;sico, mejoraron de manera similar a la tolerancia a los esfuerzos y redujeron de manera equipotente la taquicardia de reposo;</p>
      <p>2) El entrenamiento f&#237;sico y las terapias farmacol&#243;gicas aisladamente, adem&#225;s de la asociaci&#243;n del carvedilol al entrenamiento f&#237;sico, mejoraron significantemente la fracci&#243;n de acortamiento;</p>
      <p>3) Ambos metoprolol y carvedilol asociados al entrenamiento f&#237;sico redujeron similarmente la fracci&#243;n de volumen de col&#225;geno card&#237;aco y el di&#225;metro transverso de los cardiomiocitos.</p>
      <p>Anteriormente, evidenciamos que el entrenamiento f&#237;sico mejora la fracci&#243;n de acortamiento en la insuficiencia cardiaca por mejora en el transiente de calcio y del perfil de expresi&#243;n de las prote&#237;nas que regulan el flujo de Ca<sup>2+</sup> intracelular<sup>13,23</sup>. Adem&#225;s de ello, mostramos tambi&#233;n que el carvedilol es m&#225;s eficaz en reducir el estr&#233;s oxidativo que en mejorar el transiente de Ca<sup>2+</sup> card&#237;aco<sup>20</sup>. Por tanto, esta combinaci&#243;n puede potencializar los efectos ben&#233;ficos de ambas terapias sobre la funci&#243;n card&#237;aca. Ya la asociaci&#243;n del metoprolol con el entrenamiento f&#237;sico parece ser menos pronunciada, muy probablemente en virtud del metoprolol tambi&#233;n tener su efecto card&#237;aco semejante al del EF, o sea, m&#225;s asociado al transiente de calcio y no a la reducci&#243;n del estr&#233;s oxidativo<sup>20</sup>.</p>
      <p>Aunque el carvedilol y el metoprolol hayan tenido efecto diferenciado en la asociaci&#243;n con el entrenamiento f&#237;sico sobre la contractilidad ventricular, ambos, cuando asociados al entrenamiento f&#237;sico, fueron igualmente eficaces en mejorar la tolerancia a los esfuerzos.</p>
      <p>El aumento de la tolerancia a la realizaci&#243;n de esfuerzo f&#237;sico no depende exclusivamente de la mejora de la funci&#243;n card&#237;aca, sino de la asociaci&#243;n de un mejor desempe&#241;o card&#237;aco con adaptaciones ben&#233;ficas en blancos no card&#237;acos. Esto puede incluir la respuesta vasodilatadora en el endotelio vascular, en la distribuci&#243;n del gasto cardiaco y en la respuesta ventilatoria<sup>25</sup>, as&#237; como modificaciones en la musculatura esquel&#233;tica.</p>
      <p>An&#225;lisis de la estructura muscular esquel&#233;tica, realizadas en el mismo modelo gen&#233;tico utilizado en este estudio, con ratones &#945;<sub>2A</sub>/&#945;<sub>2C</sub>-ARKO, a los 7 meses de edad, por medio de la t&#233;cnica de histoqu&#237;mica para ATPase mios&#237;nica, mostraron disminuci&#243;n del &#225;rea seccional de las fibras musculares, alteraci&#243;n fenot&#237;pica de las fibras del tipo I para fibras del tipo II y rarefacci&#243;n capilar. Las alteraciones descriptas parecen todav&#237;a estar acompa&#241;adas por el cambio del perfil metab&#243;lico, con reducci&#243;n de la actividad de enzimas oxidativas<sup>26</sup>. Tal hecho puede estar asociado a la reducci&#243;n progresiva de la tolerancia al esfuerzo, observada en el presente estudio.</p>
      <p>En lo que toca a los efectos de los betabloqueantes en la tolerancia al esfuerzo, varios estudios en la literatura examinaron su uso en portadores de diversas cardiopat&#237;as<sup>27,28</sup>. Los ensayos cl&#237;nicos que perduraron por m&#225;s de un mes observaron mejoras significativas en la funci&#243;n ventricular, pero muy sutiles en la tolerancia al esfuerzo<sup>27,28</sup>. Por tanto, el entrenamiento f&#237;sico parece ejercer rol fundamental en la mejora de la tolerancia a la realizaci&#243;n de esfuerzo en la insuficiencia card&#237;aca de estos ratones, corroborando otros estudios que muestran el mismo efecto<sup>29,30</sup>.</p>
      <p>De modo parecido al resultado de la tolerancia a la realizaci&#243;n de esfuerzo, observamos comportamientos semejantes en la reducci&#243;n de frecuencia card&#237;aca en los grupos metoprolol y carvedilol asociados al entrenamiento f&#237;sico. Ambos tuvieran efecto equipotente sobre la FC, reduci&#233;ndola a valores semejantes a los observados en los ratones WT (l&#237;nea punteada) y, por tanto, mostrando la eficacia del tratamiento con los dos betabloqueantes en la disminuci&#243;n de la taquicardia presentada en este modelo de cardiomiopat&#237;a, que est&#225; relacionada a un aumento de la actividad del sistema nervioso simp&#225;tico. Tales efectos bradic&#225;rdicos, por tanto, pueden sugerir una mejora en el balance auton&#243;mico en estos ratones, que, a su vez, est&#225; relacionada a una mejora del pron&#243;stico y de la sobrevida en la insuficiencia cardiaca<sup>16,31</sup>. Adem&#225;s de ello, los valores elevados de la frecuencia card&#237;aca tambi&#233;n emergen como predictores independientes de mortalidad en la poblaci&#243;n en general<sup>32,33</sup>.</p>
      <p>Aliada a las alteraciones en la funci&#243;n ventricular, nuestros resultados tambi&#233;n sugieren la remodelaci&#243;n card&#237;aca en los ratones con insuficiencia cardiaca (<xref ref-type="fig" rid="f4-body3">Figura 4</xref>). Ambos los betabloqueantes en asociaci&#243;n con el entrenamiento f&#237;sico presentaron efectos ben&#233;ficos en la estructura card&#237;aca, lo que previno la hipertrofia de los cardiomiocitos y el aumento del col&#225;geno card&#237;aco.</p>
      <p>De hecho, el entrenamiento f&#237;sico tiene efecto en la remodelaci&#243;n reversa asociada a la reducci&#243;n en la v&#237;a de se&#241;alizaci&#243;n de la calcineurina, que est&#225; relacionada a la hipertrofia patol&#243;gica<sup>34</sup> o activaci&#243;n de la v&#237;a de Akt asociada a la hipertrofia fisiol&#243;gica<sup>35</sup>. Por tanto, la asociaci&#243;n del EF a los betabloqueantes es una conducta a adoptar, una vez que la remodelaci&#243;n est&#225; altamente relacionada al &#243;bito en pacientes con IC<sup>36-38</sup>.</p>
      <p>Otros efectos del entrenamiento f&#237;sico, minimizando el proceso de falla del miocardio, han sido recientemente evidenciados y pueden estar asociados, de entre otros factores, a la reducci&#243;n de prote&#237;nas asociadas a la fibrosis y a la remodelaci&#243;n cardiaca<sup>39,40</sup>.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La asociaci&#243;n de entrenamiento f&#237;sico a las terapias con metoprolol o carvedilol mejor&#243; de modo semejante a tolerancia al esfuerzo y mejor&#243; tambi&#233;n la estructura card&#237;aca de los ratones con IC inducida por hiperactividad simp&#225;tica. Sin embargo, solamente el carvedilol cuando asociado al EF mejor&#243; la contractilidad.</p>
      <p>
        <bold>Agradecimientos</bold>
      </p>
      <p>A la Facultad de Medicina y a la Escuela de Educaci&#243;n F&#237;sica y Deporte de la Universidad de S&#227;o Paulo. A la FAPESP por el financiamiento del estudio (06/56123-0, 05/59740-7). P. C. B. tiene una beca investigador nivel ID del CNPq (301519/2008-0).</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue financiado por la FAPESP.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Andr&#233;a Somolanji Vanzelli por la Facultad de Medicina de la Universidad de S&#227;o Paulo.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
